



## Clinical Trial Protocol

<b>Document Number:</b>		<b>c26448055-04</b>
<b>EudraCT No.</b>	2019-000507-33	
<b>BI Trial No.</b>	1371-0005	
<b>BI Investigational Medicinal Product</b>	BI 894416	
<b>Title</b>	Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in healthy male subjects (an open-label, one-way crossover study)	
<b>Lay Title</b>	A study in healthy men to test whether rifampicin influences the amount of BI 894416 in the blood	
<b>Clinical Phase</b>	I	
<b>Clinical Trial Leader</b>	     Phone: Fax:	
<b>Principal Investigator</b>	     Phone: Fax:	
<b>Status</b>	Final Protocol (Revised Protocol (based on global amendment 3))	
<b>Version and Date</b>	Version: 4.0	Date: 09 September 2019
<b>Page 1 of 67</b>		
<b>Proprietary confidential information</b>		
<b>© 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.</b> This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission		

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

## **CLINICAL TRIAL PROTOCOL SYNOPSIS**

<b>Company name</b>	Boehringer Ingelheim
<b>Protocol date</b>	11 March 2019
<b>Revision date</b>	09 September 2019
<b>BI trial number</b>	1371-0005
<b>Title of trial</b>	Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in healthy male subjects (an open-label, one-way crossover study)
<b>Principal Investigator:</b>	
<b>Trial site</b>	
<b>Clinical phase</b>	I
<b>Trial rationale</b>	Based on in vitro data, CYP3A is involved in metabolism of BI 894416. It is necessary to explore the effect of CYP3A induction on the pharmacokinetics of BI 894416.
<b>Trial objective</b>	The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416.
<b>Trial design</b>	Open-label, one-way crossover design
<b>Trial endpoints:</b>	Primary endpoints: AUC <sub>0-∞</sub> and C <sub>max</sub> of BI 894416 Secondary endpoint: AUC <sub>0-tz</sub> of BI 894416
<b>Number of subjects</b>	
<b>total entered</b>	16
<b>each treatment</b>	16
<b>Diagnosis</b>	Not applicable
<b>Main criteria for inclusion</b>	Healthy male subjects, age of 18 to 50 years (inclusive), body mass index (BMI) of 18.5 to 29.9 kg/m <sup>2</sup> (inclusive)
<b>Test product 1</b>	BI 894416 tablet (strength: 25 mg)
<b>dose</b>	50 mg
<b>mode of admin.</b>	Oral with 240 mL of water after an overnight fast of at least 10 h

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

<b>Test product 2</b>	Eremfat® 600 mg film-coated tablet (rifampicin; strength: 600 mg)
<b>dose</b>	600 mg once daily (qd) for 7 days in treatment T
<b>mode of admin.</b>	Oral with 240 mL of water
<b>Duration of treatment</b>	Treatment period 1: 50 mg BI 894416 as single dose on Day 1 (Reference – R)  Treatment period 2: 600 mg Eremfat® as single dose for 7 days (Days -7 to -1) 50 mg BI 894416 as single dose on Day 1 (Test – T)
<b>Statistical methods</b>	Relative bioavailability will be estimated by the ratios of the geometric means (test/reference) for the primary and secondary endpoints. Additionally, their two-sided 90% confidence intervals (CIs) will be provided. This method corresponds to the two one-sided t-test procedure, each at a 5% significance level. Since the main focus is on estimation and not testing, a formal hypothesis test and associated acceptance range is not specified. The statistical model will be mixed effects model on the logarithmic scale including effects for subject (random) and treatment (fixed). CIs will be calculated based on the residual error from the mixed effects model.  Descriptive statistics will be calculated for all endpoints.

## FLOW CHART

Period	Visit	Day	Planned time (relative to BI 894416 administration) [h:min]	Approximate clock time of actual day [h:min]	Event and comment	Safety laboratory <sup>7</sup>	PK <sub>blood</sub> BI 894416	PK <sub>blood</sub> rifampicin	PK urine BI 894416 <sup>11</sup>	12-lead ECG	Neurological examination <sup>8</sup>	Vital signs (BP, PR)	Questioning for AEs and concomitant therapy <sup>6</sup>
SCR	1	-21 to -2			Screening (SCR) <sup>1</sup>	A				x	x	x	
1 (BI 894416 alone)	2	1	-1	-14:00	18:00	Admission to trial site	x <sup>10</sup>						
			1	-2:00	06:00	Allocation to study subject numbers <sup>2</sup>	B <sup>2,12</sup>	x <sup>2</sup>	x <sup>2</sup>	x <sup>2</sup>		x <sup>2</sup>	x <sup>2</sup>
				0:00	08:00	<b>BI 894416 administration</b>			▲				
				0:15	08:15		x						
				0:30	08:30		x						
				0:45	08:45		x						
				1:00	09:00		x			x		x	
				1:30	09:30		x						
				2:00	10:00	240 mL fluid intake	x		x	x	x	x	
				2:30	10:30		x						
				3:00	11:00		x						
				4:00	12:00	240 mL fluid intake, thereafter lunch <sup>3</sup>	x	+				x	
				6:00	14:00		x						
				8:00	16:00	Snack (voluntary) <sup>3</sup>	x	+					
				10:00	18:00		x						
				11:00	19:00	Dinner							
				12:00	20:00		x	+			x		
			2	24:00	08:00	Discharge from trial site, breakfast <sup>3</sup> (voluntary)	B	x	▼	x	x	x	
				34:00	18:00	Ambulatory visit		x				x	
			3	48:00	08:00	Ambulatory visit		x				x	
2 (BI 894416 + rifampicin)	3	-7	-158:30	17:30	Admission to trial site <sup>2</sup>	x <sup>2,10</sup>						x <sup>2</sup>	
				-158:00	18:00	<b>Rifampicin administration</b>							
				-157:00	19:00	Dinner							
				-156:00	20:00	Discharge from trial site						x	
		-6	-134:00	18:00	Ambulatory visit, <b>rifampicin administration</b>							x	
				-110:00	18:00	Ambulatory visit, <b>rifampicin administration</b>						x	
				-86:00	18:00	Ambulatory visit, <b>rifampicin administration</b>						x	
				-62:00	18:00	Ambulatory visit, <b>rifampicin administration</b>		x <sup>9</sup>				x	
		-2	-38:00	18:00	Ambulatory visit, <b>rifampicin administration</b>	C <sup>9</sup>	x <sup>9</sup>					x	
				-14:30	17:30	Admission to trial site <sup>2</sup>						x <sup>2</sup>	
				-14:00	18:00	<b>Rifampicin administration</b>		x <sup>9</sup>					
				-13:00	19:00	Dinner							
				-12:00	20:00			x					

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

## FLOW CHART (cont'd)

Period	Visit	Day	Planned time (relative to BI 894416 administration) [h:min]	Approximate clock time of actual day [h:min]	Event and comment	Safety laboratory <sup>7</sup>	PK <sub>blood</sub> BI 894416	PK <sub>blood</sub> rifampicin	PK <sub>urine</sub> BI 894416 <sup>11</sup>	12-lead ECG	Neurological examination <sup>8</sup>	Vital signs (BP, PR) <sup>9</sup>	Questioning for AEs and concomitant therapy <sup>6</sup>
2 (BI 894416 + rifampicin)	3	1	-2:00	06:00		B <sup>2</sup>	x <sup>2</sup>		x <sup>2</sup>	x <sup>2</sup>		x <sup>2</sup>	x <sup>2</sup>
			0:00	08:00	BI 894416 administration			▲					
			0:15	08:15		x							
			0:30	08:30		x							
			0:45	08:45		x							
			1:00	09:00		x			x	x	x		
			1:30	09:30		x							
			2:00	10:00	240 mL fluid intake	x			x	x	x	x	x
			2:30	10:30		x							
			3:00	11:00		x							
			4:00	12:00	240 mL fluid intake, thereafter lunch <sup>3</sup>	x		+				x	
			6:00	14:00		x							
			8:00	16:00	Snack (voluntary) <sup>3</sup>	x		+					
			10:00	18:00		x							
			11:00	19:00	Dinner								
			12:00	20:00		x		+				x	
		2	24:00	08:00	Discharge from trial site, breakfast <sup>3</sup> (voluntary)	B	x	▼	x		x	x	x
			34:00	18:00	Ambulatory visit		x					x	
		3	48:00	08:00	Ambulatory visit		x					x	
FU	4	8 to 15			End of trial (EoTrial) examination <sup>4</sup>	B				x	x	x	x

1. Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening procedures include physical examination, neurological examination, check of vital signs, ECG, safety laboratory (including drug screening and Cotinine test), demographics (including determination of body height and weight, smoking status and alcohol history), relevant medical history, concomitant therapy and review of inclusion/exclusion criteria.
2. The time is approximate; the procedure is to be performed and completed within the 3 h prior to the next drug administration.
3. If several actions are indicated at the same time, the intake of meals will be the last action.
4. At the end of trial visit the EoTrial examination includes physical examination, neurological examination, vital signs, ECG, safety laboratory, recording of AEs and concomitant therapies.
5. Including urine drug screening and alcohol breath test
6. AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times indicated in the [Flow Chart](#) above.
7. Letters A, B, and C define different sets of safety laboratory examinations (see Section [5.2.3](#))
8. Unscheduled neurological examinations may be added at any time during the trial for individual volunteers or the whole treatment group, e.g., in case of neurological adverse events, if assessed as necessary by the investigator.
9. Within 15 min of next drug administration
10. Only urine drug screening and alcohol breath test
11. A blank urine sample (x) is to be obtained prior to administration of trial medication. Other urine samples are to be collected over the stated post-dose intervals (◀—|—|▶) 0-4, 4-8, 8-12, and 12-24 h.
12. Pharmacogenetic samples will be collected at Day 1 prior to administration.

## TABLE OF CONTENTS

<b>TITLE PAGE .....</b>	<b>1</b>
<b>CLINICAL TRIAL PROTOCOL SYNOPSIS .....</b>	<b>2</b>
<b>FLOW CHART .....</b>	<b>4</b>
<b>TABLE OF CONTENTS .....</b>	<b>6</b>
<b>ABBREVIATIONS .....</b>	<b>10</b>
<b>1. INTRODUCTION.....</b>	<b>13</b>
1.1 MEDICAL BACKGROUND.....	13
1.2 DRUG PROFILE .....	14
1.2.1 BI 894416 .....	14
1.2.2 Rifampicin .....	14
1.2.3 Residual Effect Period .....	15
1.3 RATIONALE FOR PERFORMING THE TRIAL.....	16
1.4 BENEFIT - RISK ASSESSMENT .....	16
1.4.1 Expected benefit to the target population.....	16
1.4.2 Procedure-related risks .....	17
1.4.3 Drug-related risks and safety measures.....	17
1.4.3.1 Risks related to BI 894416.....	17
1.4.3.2 Risks related to rifampicin .....	20
1.4.3.3 Risks related to combined administration of BI 894416 and rifampicin.....	21
1.4.3.4 Drug-induced liver injury .....	21
1.4.4 Overall assessment of benefit-risk ratio.....	22
<b>2. TRIAL OBJECTIVES AND ENDPOINTS.....</b>	<b>23</b>
2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS .....	23
2.1.1 Main objectives.....	23
2.1.2 Primary endpoints .....	23
2.1.3 Secondary endpoint .....	23
<b>3. DESCRIPTION OF DESIGN AND TRIAL POPULATION.....</b>	<b>25</b>
3.1 OVERALL TRIAL DESIGN AND PLAN .....	25
3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUP .....	25
3.3 SELECTION OF TRIAL POPULATION .....	26

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

3.3.1	Main diagnosis for trial entry .....	26
3.3.2	Inclusion criteria .....	26
3.3.3	Exclusion criteria .....	26
3.3.4	Withdrawal of subjects from treatment or assessments .....	28
3.3.4.1	Discontinuation of trial treatment .....	28
3.3.4.2	Withdrawal of consent to trial participation .....	29
3.3.4.3	Discontinuation of the trial by the sponsor .....	29
3.3.5	Replacement of subjects .....	29
<b>4.</b>	<b>TREATMENTS.....</b>	<b>30</b>
4.1	INVESTIGATIONAL TREATMENTS .....	30
4.1.1	Identity of the Investigational Medicinal Products .....	30
4.1.2	Selection of doses in the trial.....	30
4.1.3	Method of assigning subjects to treatment groups .....	31
4.1.4	Drug assignment and administration of doses for each subject .....	32
4.1.5	Blinding and procedures for unblinding .....	33
4.1.6	Packaging, labelling, and re-supply .....	33
4.1.7	Storage conditions.....	33
4.1.8	Drug accountability .....	33
4.2	OTHER TREATMENTS, EMERGENCY PROCEDURES, RESTRICTIONS .....	34
4.2.1	Other treatments and emergency procedures.....	34
4.2.2	Restrictions .....	34
4.2.2.1	Restrictions regarding concomitant treatment .....	34
4.2.2.2	Restrictions on diet and life style.....	34
4.3	TREATMENT COMPLIANCE .....	35
<b>5.</b>	<b>ASSESSMENTS .....</b>	<b>36</b>
5.1	ASSESSMENT OF EFFICACY .....	36
5.2	ASSESSMENT OF SAFETY.....	36
5.2.1	Physical examination .....	36
5.2.2	Vital signs.....	36
5.2.3	Safety laboratory parameters .....	36
5.2.4	Electrocardiogram .....	38
5.2.5	Other safety parameters.....	39
5.2.5.1	Neurological examination.....	39
5.2.6	Assessment of adverse events.....	40
5.2.6.1	Definitions of adverse events.....	40

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

5.2.6.1.1	Adverse event .....	40
5.2.6.1.2	Serious adverse event .....	40
5.2.6.1.3	AEs considered 'Always Serious' .....	40
5.2.6.1.4	Adverse events of special interest .....	41
5.2.6.1.5	Intensity (severity) of AEs.....	42
5.2.6.1.6	Causal relationship of AEs .....	42
5.2.6.2	Adverse event collection and reporting .....	43
5.2.6.2.1	AE collection .....	43
5.2.6.2.2	AE reporting to the sponsor and timelines .....	44
5.2.6.2.3	Information required.....	44
<b>5.3</b>	<b>DRUG CONCENTRATION MEASUREMENTS AND PHARMACOKINETICS .....</b>	<b>44</b>
5.3.1	Assessment of pharmacokinetics .....	44
5.3.2	Methods of sample collection .....	44
5.3.2.1	Blood sampling for pharmacokinetic analysis .....	44
5.3.3	Analytical determinations .....	46
5.3.3.1	Analytical determination of analyte plasma concentration.....	46
5.3.3.2	Analytical determination of analyte urine concentration.....	47
<b>5.4</b>	<b>BIOBANKING .....</b>	<b>47</b>
<b>5.6</b>	<b>APPROPRIATENESS OF MEASUREMENTS .....</b>	<b>47</b>
<b>6.</b>	<b>INVESTIGATIONAL PLAN.....</b>	<b>48</b>
6.1	VISIT SCHEDULE.....	48
6.2	DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS .....	48
6.2.1	Screening period.....	48
6.2.2	Treatment periods.....	48
6.2.3	Follow-up period and trial completion .....	49
<b>7.</b>	<b>STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE .....</b>	<b>50</b>
7.1	STATISTICAL DESIGN – MODEL .....	50
7.2	NULL AND ALTERNATIVE HYPOTHESES .....	50
7.3	PLANNED ANALYSES .....	50
7.3.1	Primary endpoint analyses.....	51
7.3.2	Secondary endpoint analyses .....	52
7.3.4	Safety analyses.....	53
7.4	INTERIM ANALYSES .....	54
7.5	HANDLING OF MISSING DATA .....	54
7.5.1	Safety.....	54

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

7.5.2 Pharmacokinetics.....	54
7.6 RANDOMISATION .....	54
7.7 DETERMINATION OF SAMPLE SIZE .....	54
<b>8. INFORMED CONSENT, TRIAL RECORDS, DATA PROTECTION, PUBLICATION POLICY, AND ADMINISTRATIVE STRUCTURE .....</b>	<b>56</b>
8.1 TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT .....	56
8.2 DATA QUALITY ASSURANCE .....	57
8.3 RECORDS .....	57
8.3.1 Source documents .....	57
8.3.2 Direct access to source data and documents.....	58
8.3.3 Storage period of records .....	58
8.4 EXPEDITED REPORTING OF ADVERSE EVENTS .....	58
8.5 STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY.....	58
8.5.1 Collection, storage and future use of biological samples and corresponding data .....	59
8.6 TRIAL MILESTONES .....	59
8.7 ADMINISTRATIVE STRUCTURE OF THE TRIAL .....	60
<b>9. REFERENCES .....</b>	<b>61</b>
9.1 PUBLISHED REFERENCES.....	61
9.2 UNPUBLISHED REFERENCES.....	62
<b>10. APPENDICES .....</b>	<b>64</b>
<b>11. DESCRIPTION OF GLOBAL AMENDMENT(S) .....</b>	<b>65</b>
11.1 GLOBAL AMENDMENT (REVISED PROTOCOL).....	65
11.2 GLOBAL AMENDMENT 2 .....	66
11.3 GLOBAL AMENDMENT 3 .....	67

## **ABBREVIATIONS**

ADME	Absorption, distribution, metabolism, and excretion
ADP	Adenosine diphosphate
AE	Adverse event
AESI	Adverse events of special interest
ALCOA	Attributable, legible, contemporaneous, original, and accurate
AUC <sub>0-∞</sub>	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
AUC <sub>0-tz</sub>	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point
BA	Bioavailability
BI	Boehringer Ingelheim
BMI	Body mass index (weight divided by height squared)
BP	Blood pressure
CA	Competent authority
CI	Confidence interval
C <sub>max</sub>	Maximum measured concentration of the analyte in plasma
CRF	Case Report Form, paper or electronic (sometimes referred to as 'eCRF')
CTM	Clinical Trial Manager
CTP	Clinical Trial Protocol
CTR	Clinical Trial Report
CYP	Cytochrome P450 superfamily
CYP1A1	Cytochrome P450 isoenzyme 1A1
CYP2B6	Cytochrome P450 isoenzyme 2B6
CYP2C19	Cytochrome P450 isoenzyme 2C19
CYP2C8	Cytochrome P450 isoenzyme 2C8
CYP2C9	Cytochrome P450 isoenzyme 2C9

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

CYP3A	Cytochrome P450 subfamily 3A
CYP3A4	Cytochrome P450 isoenzyme 3A4
DILI	Drug induced liver injury
DNA	Deoxyribonucleic acid
EC	Ethics Committee
ECG	Electrocardiogram
eCRF	Electronic case report form
eDC	Electronic data capture
EDTA	Ethylenediaminetetraacetic acid
EEG	Electroencephalogram
EoTrial	End of trial
EudraCT	European Clinical Trials Database
FDA	Food and Drug Administration

FU	Follow-up
GCP	Good Clinical Practice
gCV	Geometric coefficient of variation
gMean	Geometric mean
HPC	Human Pharmacology Centre
IB	Investigator's Brochure
ICF	Informed Consent Form
IEC	Independent Ethics Committee
IPV	Important Protocol Violation
IQRMP	Integrated Quality and Risk Management Plan
IRB	Institutional Review Board
ISF	Investigator Site File

LC-MS/MS	Liquid chromatography with tandem mass spectrometry
MDA	Methylenedioxymphetamine
MDMA	Methylenedioxymethamphetamine
MedDRA	Medical Dictionary for Regulatory Activities
MRT <sub>ex</sub>	Mean residence time of the analyte in the body, extravascular
NK cell	Natural killer cell
PE	Polyethylene
PK	Pharmacokinetic(s)
PKS	Pharmacokinetic set
PP	Polypropylene

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

PR	Pulse rate
q.d.	Once daily
QT	Time between start of the Q-wave and the end of the T-wave in an electrocardiogram
QTc	QT interval corrected for heart rate using the method of Fridericia (QTcF) or Bazett (QTcB)
R	Reference treatment
REP	Residual effect period
RNA	Ribonucleic acid
SAE	Serious Adverse Event
SCR	Screening
SPC	Summary of Product Characteristics
SOP	Standard Operating Procedure
SRD	Single-rising dose
SUSAR	Suspected unexpected serious adverse reaction
SYK	Spleen tyrosine kinase
T	Test product or treatment
TS	Treated set
TSAP	Trial statistical analysis plan
ULN	Upper limit of normal
WOCBP	Woman of child bearing potential
XTc	Ecstasy

## **1. INTRODUCTION**

BI 894416 is an oral, selective non-receptor protein tyrosine kinase SYK (spleen tyrosine kinase) inhibitor under clinical development for the indication of uncontrolled severe persistent asthma.

This trial will be performed to investigate the effect of multiple oral doses of the strong CYP3A inducer rifampicin [[R18-0241](#)] on the single dose pharmacokinetics of BI 894416.

### **1.1 MEDICAL BACKGROUND**

Asthma is a heterogenous disease characterized by a chronic inflammatory process of the airways and driven by both the innate and adaptive immune pathways [[R14-4230](#), [P08-01263](#)]. In severe asthma, the T type 2 inflammation (T2) -high and T2-low, and the non-T2 pathways are involved associated with a mixed pattern of inflammation involving eosinophil, basophil, mast, neutrophil, innate lymphoid and dendritic cells [[R15-5888](#), [R16-0945](#)].

SYK is a non-receptor cytoplasmic tyrosine kinase that is predominantly expressed in cells of hematopoietic lineage, including B cells, T cells, monocytes, NK cells, mast cells, basophils, and neutrophils [[R15-5470](#)]. SYK is a key component of the signal transduction associated with the T2-high and T2-low, and non-T2 asthma pathways that is activated through interaction with allergens and a number of innate and adaptive immune receptors including Fc receptors on basophils, mast, B- and T cells. SYK is essential for the Fc $\epsilon$ R1-mediated activation and degranulation of mast cells and basophils. SYK is also important in the signal propagation of the dectin family of innate receptors, present on macrophages, dendritic cells and neutrophils. Furthermore, SYK has important roles in B-cell and T-cell development, with partially redundant functions with Zeta-chain-associated protein kinase of 70 kDa (ZAP70) [[R15-5470](#), [R16-5298](#)].

For more details on medical background see the current version of the Investigator's Brochure (IB) [[c03536505-04](#)].

## 1.2 DRUG PROFILE

### 1.2.1 BI 894416

BI 894416 is a potent and selective inhibitor of SYK. Based on pre-clinical *in vitro* and *in vivo* data, SYK inhibition is expected to have effect on the non-T2 and T2 inflammatory pathway components of severe asthma.

So far, BI 894416 was investigated in one clinical phase I first-in-man trial (BI study number 1371-0001) and one clinical phase I drug-drug interaction trial (BI study number 1371-0004) in healthy male volunteers.

Trial 1371-0001 consisted of two trial parts, a single-rising dose (SRD) part and a relative bioavailability (rel BA) part. Single-dose treatment with up to 70 mg BI 894416 or placebo as oral solution in the SRD part of trial 1371-0001 as well as administration of three single doses (10, 10, and 40 mg BI 894416) as tablet or oral solution in the rel BA part was safe and well tolerated. For details on safety and tolerability as well as on pharmacokinetics and biomarker data of trial 1371-0001 refer to the IB [[c03536505-04](#)].

Trial 1371-0004 investigated the effect of strong inhibition of CYP3A and inhibition of P-glycoprotein on an oral single dose of BI 894416. In that trial 3 mg BI 894416 was given without (period 1) or together with 200 mg itraconazole q.d. (period 2; 3 days pre-treatment, a fourth dose of itraconazole 1 h before BI 894416, and a fifth dose of itraconazole 23 h following BI 894416 dosing). Preliminary PK data (based on planned time points) indicate that the ratios of  $C_{max}$ ,  $AUC_{0-tz}$  and  $AUC_{0-\infty}$  of BI 894416 in plasma when given together with itraconazole and when given alone were 113.32%, 141.96%, and 142.92%, respectively. BI 894416, alone or together with itraconazole, was assessed as safe and well-tolerated in trial 1371-0004. For more details refer to the IB [[c03536505-04](#)].

For a more detailed description of the BI 894416 profile, please refer to the current Investigator's Brochure (IB) [[c03536505-04](#)].

### 1.2.2 Rifampicin

Rifampicin is a broad-spectrum antibiotic that can be used to treat infections such as tuberculosis, leprosy, and other mycobacterial infections, and for prophylaxis of e.g. meningococcal meningitis [[R19-2541](#)]. Rifampicin inhibits bacterial RNA polymerase. The dosage of rifampicin in adults in the treatment of tuberculosis is usually between 450 and 600 mg/day [[R19-2541](#)].

FDA recommends rifampicin as strong index inducer of CYP3A and CYP2C19 and as moderate index inducer of CYP2B6, CYP2C8, and CYP2C9 [[R18-0241](#)].

#### Pharmacokinetics

Rifampicin is readily absorbed from the gastrointestinal tract. Intake of rifampicin with a high-fat meal may reduce  $C_{max}$  and AUC by 25-30% and by 6-23%, respectively, and may delay  $t_{max}$  by a factor of 2. Rifampicin has a large volume of distribution, and approximately 70-90% is plasma-protein bound. Rifampicin is metabolized in the liver by CYP enzymes to

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

its main metabolite 25 desacetyl rifampicin. Due to rifampicin-mediated induction of CYP enzymes, plasma elimination half-life of rifampicin decreases with multiple-dose administration. Elimination half-life of rifampicin may be between 3 and 16 hours and is influenced by enterohepatic circulation. [\[R19-2541\]](#)

Rifampicin induces a number of drug-metabolising enzymes, having the greatest effects on the expression of CYP3A4 in the liver and in the small intestine. It induces several other CYP enzymes as well including CYP2C19, 2B6, 2C8 and 2C9 [\[R18-0241\]](#). In addition, rifampicin induces some drug transporters, such as intestinal P-glycoprotein [\[P14-07656\]](#).

Full induction of drug-metabolising enzymes may be reached in about 1 week after starting rifampicin treatment, and the induction may dissipate in roughly 2 weeks after discontinuing rifampicin [\[P03-08008\]](#).

### *Safety*

Very common adverse reactions to rifampicin are elevations of liver enzymes. In some patients hyperbilirubinaemia can occur in the early days of treatment. This is thought to result from competition between rifampicin and bilirubin for hepatic excretion. Very rarely, acute hepatitis is caused by rifampicin. Monitoring of liver function tests is recommended.

Common adverse reactions are gastro-intestinal reactions including anorexia, nausea, vomiting, abdominal pain, meteorism, and diarrhoea as well as mild hypersensitivity reactions such as fever, erythema exsudativum multiforme, itching with or without skin rash, and urticaria. More serious hypersensitivity reactions have been reported but are rare (dyspnea, asthma-like episodes, pulmonary edema, other edema, anaphylactic shock) or very rare (lupus-like syndrome, flu syndrome, severe allergic skin reactions). Pseudomembranous colitis has been reported with rifampicin therapy in very rare cases.

For a more detailed description of rifampicin please refer to the current version of the summary of product characteristics (SPC) [\[R19-2541\]](#).

### **1.2.3 Residual Effect Period**

The Residual Effect Period (REP, i.e., the period after the last dose with measurable drug levels and/or pharmacodynamic effects still likely to be present) of BI 894416 has not been defined yet. However, the elimination half-life of BI 894416 is short (gMean terminal half-life between 2.96 and 5.31 h in the SRD part of trial 1371-0001), the mode of action is reversible, and safety and tolerability in previous trial 1371-0001 were good. This suggests that the occurrence of any potential adverse effects would likely be of short duration (i.e. few days). When given together with rifampicin, it is expected that plasma exposure of BI 894416 could be decreased as a result of CYP enzyme and/or P-glycoprotein induction and the time of relevant plasma exposure could be shortened. An increase of BI 894416 plasma exposure when given with rifampicin in this trial is not expected.

The follow-up visit is earliest on Day 8 following BI 894416 dosing in period 2, as this is expected to cover the period in which any potential adverse effects could reasonably occur.

For the use of rifampicin in this trial, the REP is defined as 6 days.

### **1.3 RATIONALE FOR PERFORMING THE TRIAL**

Based on in vitro data, CYP3A is major responsible enzyme for metabolism of BI 894416.

Preliminary results of drug-drug interaction trial 1371-0004 indicated only a minor increase of BI 894416 plasma exposure parameters when given with itraconazole (see Section [1.2.1](#)). However, the extent of the effect of concomitant administration of a CYP3A and P-glycoprotein inducer on BI 894416 pharmacokinetics is unclear. Assessment is necessary to inform concomitant treatment recommendations in patient studies.

This clinical trial will be performed to investigate the effect of multiple doses of rifampicin on the pharmacokinetics of a single dose of BI 894416 in order to assess if and to which extent the pharmacokinetics of BI 894416 are affected by induction of CYP3A.

Rifampicin is chosen for this trial as perpetrator drug, as this drug is recommended as strong index inducer of CYP3A by FDA [[R18-0241](#)].

### **1.4 BENEFIT - RISK ASSESSMENT**

Participation in this clinical trial is without any (therapeutic) benefit for healthy subjects. Their participation, however, is of major importance for the development of BI 894416. Subjects are exposed to risks of study procedures and risks related to the exposure to the trial medication.

#### **1.4.1 Expected benefit to the target population**

Asthma is a heterogeneous disease that is driven by the innate and adaptive immune pathway. In severe asthma, both the T2-high and T2-low, and the non-T2 inflammation pathways are involved, and associated with a mixed pattern of inflammation involving eosinophil, basophil, mast, neutrophil, innate lymphoid and dendritic cells. Up to 50% of severe asthma is driven by the non T2 and/or T2-low alone or in combination with the T2-high pathway. This non T2 / T2-low component represents an area of unmet medical need that does not respond to high dose inhaled corticosteroids or other current controller therapy, and is unlikely to respond to the T2-high monoclonal antibodies targeted therapies.

SYK is a key component of signal transduction associated with the T2-high and T2-low, and non-T2 asthma pathways that is activated through interaction with allergens and a number of innate and adaptive immune receptors including Fc receptors on basophils, mast, B and T cells. SYK is also important in the signal propagation of the dectin family of innate receptors, present on macrophages, dendritic cells and neutrophils.

Such a therapy would meet a substantial unmet need for severe asthma patients, especially those with a non T2 and/or T2-low component, whether early/late-onset or steroid resistant, and could become a safe and effective alternate also in T2 asthma to high dose inhaled corticosteroids, oral systemic corticosteroids or T2-high biological monoclonal antibodies.

#### 1.4.2 Procedure-related risks

The use of an indwelling venous catheter or venepuncture for e.g. blood sampling may result in mild bruising, and in rare cases, in transient inflammation of the wall of the vein, or nerve injury, potentially resulting in paraesthesia, reduced sensibility, and/or pain for an indefinite period.

ECG electrodes may cause local and typically transient skin reactions.

The total volume of blood withdrawn per subject during the entire study will not exceed the volume of a normal blood donation (500 mL). No health-related risk to healthy subjects is expected from withdrawal of this volume of blood.

#### 1.4.3 Drug-related risks and safety measures

##### 1.4.3.1 Risks related to BI 894416

###### Potential effects on immune cells

SYK is involved in the function of basophil, mast, neutrophil and dendritic cells. Moreover, SYK is implicated in the development and function of both T cells and B cells. For details refer to the IB [[c03536505-04](#)].

The risk for healthy volunteers due to effects of BI 894416 on immune cells is expected to be minimal, for the following reasons:

- Inhibition of SYK is not expected to have a negative effect with regards to the immune response of innate immune cells to viral or bacterial infections due to redundancy in the infection immune response. The key neutrophil and dendritic cell functions most likely will be triggered by alternative pathways.
- Safety and tolerability data of trial 1371-0001 are not suggestive of an increased risk of infectious adverse events or of any relevant BI 894416-related findings in WBC, differential blood count, immunoglobulins, or lymphocyte subpopulations after single doses up to 70 mg BI 894416 (see also IB [[c03536505-04](#)]).
- Due to the reversible mode of action of BI 894416 with regards to SYK inhibition, any potential effects on immune cells are expected to be of transient nature.

*Risk mitigation and monitoring:* Subjects with a history or diagnosis of relevant immunological disease will be excluded from trial participation (see Section [3.3.3](#)). Adverse events will be monitored for an increase in infectious adverse events. Safety laboratory contains WBC, differential blood count, and CRP.

###### Tumour biology and carcinogenicity

The SYK pathway has been hypothesized to act as both a tumour suppressor and a tumour promoter in different types of human cancers [[R16-4459](#)]. An increased risk of carcinogenic/metastatic potential in epithelial cancers has been reported in the literature related to SYK knock-out, but not related to SYK inhibition. Allelic deletion of SYK has

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

been associated with breast adenocarcinoma [[R15-4770](#)]. However, there is no evidence that pharmacologic inhibition of SYK will increase carcinogenicity or metastatic risk. Preclinical data with a potent and selective tool SYK inhibitor, BI 1002494, are in line with an absence of a carcinogenic effect due to inhibition of SYK enzymatic function [[n00243171](#)].

*Risk mitigation and monitoring:* Only male subjects are included in this trial. In view of the extended time necessary to induce a carcinogenic effect, two single doses of BI 894416 are not considered a relevant carcinogenic risk to male subjects participating in this study. Accordingly, no further risk mitigation is required in this study.

#### Platelet aggregation and bleeding risk

A role of SYK in platelet function has been demonstrated in literature [[R15-5470](#)]. Several platelet functions rely on SYK signalling (e.g. collagen receptor GPVI) but others are independent of SYK [[R16-5240](#)]. *In vitro* studies using human platelets demonstrated that at concentrations up to 100 µM, BI 894416 had no effect on extrinsic or intrinsic coagulation pathways. Also, BI 894416 did not inhibit ADP-induced platelet aggregation up to 100 µM. However, BI 894416 inhibited collagen- and arachidonic acid-induced platelet aggregation at 3 µM and 5 µM. However, platelet function as measured by bleeding time is not affected by a drug unless all the platelet pathways are inhibited due to redundancy within the system. Therefore, no risk for bleeding exists with regard to platelet inhibition unless a subject is also on another antiplatelet drug that blocks these other pathways. In line with this conclusion, data of previous trial 1371-0001 do not indicate any signs of an increased risk of bleeding.

*Risk mitigation and monitoring:* Use of any other concomitant drug that could reasonably inhibit platelet aggregation or coagulation (e.g. acetylsalicylic acid) will be prohibited (see Sections [3.3.3](#) and [4.2.2.1](#)). Adverse events will be monitored for any signs of bleeding or bleeding-related adverse events.

#### Bone density

SYK is reported to be involved in osteoclast differentiation, development and function. For details see the IB [[c03536505-04](#)]. In this trial, each subject is treated with two single doses of BI 894416. Due to comparatively slow turnover of bone tissue, no relevant effect on bone is expected due to two single-dose administrations with BI 894416 in this trial, and no specific monitoring of bone density is necessary or reasonable in this trial.

#### Mortality / morbidity in preclinical studies

Mortality / sacrifice due to morbidity occurred in CByB6F1 non-transgenic mice and in Wistar Han rats. Clinical signs preceding morbidity were similar in both rodent species and included respiratory changes (rapid, shallow, and/or labored breathing), decreased motor activity, ruffled fur, hunched or prostrate posture, eye changes (squinting, discharge) and/or hypothermia. One humane sacrifice due to overt neurotoxicity was done in one dog of the 3-day escalation study. For details see the current version of the IB [[c03536505-04](#)].

*Risk mitigation and monitoring:* Data of previous trial 1371-0001 indicate good safety and tolerability of BI 894416 at all investigated doses (single oral doses up to 70 mg). The dose of

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

BI 894416 given in this trial is lower than doses given previously to healthy volunteers, and no increase of exposure of BI 894416 is expected when given with rifampicin. That means, BI 894416 plasma exposures expected in this trial are in the range measured previously in trial 1371-0001 and that were associated with good safety and tolerability. Moreover, subjects will be in-house at the trial site under close medical observation for 24 h after administration of BI 894416. Vital signs and ECGs will be measured during the trial, and subjects will be instructed to report AEs spontaneously and will be asked at pre-defined time points for AEs. In case of AEs in need of treatment, the investigator can authorise symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, kept under supervision at the trial site or transferred to a hospital until all medical evaluation results have returned to an acceptable level.

### Neurotoxicity

In dog toxicology studies, acute adverse neurological effects with tremor and movement disorder assessed as dyskinesia (paresis / rigidity) were observed at high exposures (see IB [[c03536505-04](#)]). One dog was euthanized due to overt neurotoxicity in 3-day escalation study at 90 mg/kg/day. In dose escalation study in dogs with assessment of neurotoxicity [[n00245394](#)], all clinical signs of neurotoxicity were reversible with cessation of dosing. No structural changes were observed on histopathology. Peripheral nerve conduction velocity and EEG were unchanged. No specific mechanism causing the neurological effects in dogs has been elucidated. Therefore, it has not been determined whether the neurological changes are species specific; however, external expert review considered this is most likely a channelopathy specific to dog and not likely to occur in man (see IB).

*Risk mitigation and monitoring:* Subjects with relevant neurological disorder in the medical history are excluded from trial participation (see Section [3.3.3](#), criteria 7 and 22). Neurological examinations as described in Section [5.2.5.1](#) will be performed at screening, and subjects with clinically relevant findings in the neurological examination will be excluded from study participation (see Section [3.3.3](#), criterion 1). If necessary (investigator decision), unscheduled neurological examinations may be performed at any time during the trial. Relevant findings in the neurological examination during the trial will be reported as AEs. If necessary, subjects may be sent for further, more specific evaluation and treatment to a local neurologist.

### Genotoxicity, reproductive and developmental toxicity

Genetic toxicology results by weight of evidence indicate that BI 894416 is not mutagenic or clastogenic. In the 2-week repeat dose range finding study in male rats [[n00240179](#)], degeneration of spermatids of the testes was observed at  $\geq 400$  mg/kg/day, which is considered a secondary effect, related to overt toxicity and morbidity.

It is unknown whether BI 894416 or its metabolites are distributed into male semen. Theoretically there is therefore a risk for exposure of a study subject's female partner who is a woman of child bearing potential (WOCBP) to subtherapeutic exposures of BI 894416 or its metabolites via male semen. Developmental and reproductive studies have not yet been conducted, therefore the effect of subtherapeutic concentrations of BI 894416 or its metabolites with regards to embryofetal risk has not been explored so far.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

*Risk mitigation:* In order to address the risk of exposure of a subject's female WOCBP partner to BI 894416 or its metabolites via the subject's seminal fluid, subjects need to use barrier contraception (condom) or abstinence (see Section [3.3.3](#)).

### Phototoxicity

Subjects will be advised to avoid direct exposure to sun and UV light during the entire study (see Section [4.2.2.2](#)). Further protective measures would not be necessary given the low phototoxic potential of BI 894416.

### Potential effects on QT interval

Preclinical studies suggested no proarrhythmic potential or cardiovascular liability with BI 894416. However, statistical results of first-in-man trial 1371-0001 showed a most-likely dose- and concentration-dependent increase of QTcF interval. At gMean  $C_{max}$  of the 70 mg dose group, placebo- and baseline-corrected predicted mean QTcF increase was 5.9 ms (upper limit of the 90% CI was 10.5 ms). It is expected that plasma concentrations reached in current trial 1371-0005 are lower than the maximal plasma concentrations reached in trial 1371-0001.

*Risk mitigation:* Subjects with cardiovascular disorders (Section [3.3.3](#), exclusion criterion 5), subjects who used drugs that cause QT/QTc prolongation (Section 3.3.3, exclusion criterion 11), subjects that show a marked baseline prolongation of QT/QTc interval or any other relevant ECG finding at screening (Section 3.3.3, exclusion criterion 19), and subjects with a history of additional risk factors for Torsade de Pointes arrhythmia (Section [3.3.3](#), exclusion criterion 20) are excluded from trial participation. Moreover, subjects are in-house under close observation for 24 h following drug administration, and ECGs are done pre- and post-dose at the time points given in the [Flow Chart](#). Considering these risk-mitigating measures, the risks to subjects participating at trial 1371-0005 due to potential effects on QT interval are considered minimal.

#### 1.4.3.2 Risks related to rifampicin

Rifampicin will be dosed for a limited period of time, i.e. 7 days during the present study at a clinical standard dose of 600 mg once daily. Multiple dose-administration of rifampicin is commonly used in drug-drug interaction trials involving healthy subjects because it allows investigating the impact of administration of a strong CYP3A inducer on the pharmacokinetics of co-administered (investigational) drugs.

In previous trials in healthy volunteers performed by us, administration of rifampicin for up to 12 days was of acceptable safety and tolerability [[U09-1349-01](#), [U10-1328-01](#), [U12-1140-01](#), [U13-1478-01](#)]. A typical side effect after administration of rifampicin to healthy subjects is reversible chromaturia. The colour of the urine may vary between orange, dark, orange, red, red-brown, and brown. Rarely, rifampicin can cause disturbances of blood count, such as leukopenia, neutropenia or thrombopenia. Frequently, mild hypersensitivity reactions can occur. Severe hypersensitivity reactions are rare or very rare. Frequently, gastrointestinal

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

symptoms are reported. Very frequent are increases of ALAT, ASAT, AP or gGT. Uncommon are icterus and hepatomegaly and acute hepatitis is very rare. A full listing of the reported side effects of rifampicin can be found in [R19-2541].

*Risk mitigation:*

- Safety and tolerability will be closely monitored during the trial, including regular assessment of adverse events and safety laboratory.
- Subjects will be instructed to report AEs spontaneously and will be asked at pre-defined time points for AEs. In case of AEs in need of treatment, the investigator can authorise symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, kept under supervision at the trial site or transferred to a hospital until all medical evaluation results have returned to an acceptable level.
- Individual treatment will be stopped if pre-specified criteria are met (see Section 3.3.4.1). To account for the risk of rifampicin to very rarely cause acute hepatitis, an increase of ALAT and/or ASAT  $>2\times$  ULN triggers stopping of individual treatment of a subject.
- A thorough screening examination will ensure that only suitable healthy subjects will enter the study.
- Only subjects with liver enzyme values that do not exceed the ULN will be included into the study (see Section 3.3.3, criterion 25).

Considering these safety measures and taking into account the reported acceptable tolerability of rifampicin in healthy subjects, the planned administration of rifampicin does not represent an undue risk to healthy volunteers.

#### 1.4.3.3 Risks related to combined administration of BI 894416 and rifampicin

##### Potential effects of BI 894416 on rifampicin pharmacokinetics and side effects

The last dose of rifampicin will be given 14 hours prior to BI 894416 in period 2. In this trial, no relevant effect of BI 894416 on rifampicin pharmacokinetics or side effects is expected.

##### Expected effects of rifampicin on BI 894416 pharmacokinetics and side effects

It is expected that BI 894416 plasma concentrations decrease when given following a 1-week treatment with rifampicin. This is not expected to increase the risk of side effects of BI 894416.

#### 1.4.3.4 Drug-induced liver injury

Although rare, a potential for drug-induced liver injury (DILI) is under constant surveillance by sponsors and regulators. Therefore, this trial requires timely detection, evaluation, and follow-up of laboratory alterations in selected liver laboratory parameters to ensure subjects' safety; see also Section 5.2.6.1.4, adverse events of special interest.

#### **1.4.4 Overall assessment of benefit-risk ratio**

BI 894416 is a highly specific SYK inhibitor that has been adequately characterised in pre-clinical studies. The non-clinical safety package supports administration of BI 894416 for up to 4 weeks duration to men.

Data of previous trial 1371-0001 indicate good safety and tolerability of single oral doses of BI 894416 at all dose levels, i.e. up to 70 mg. In addition, data from oral administration of three SYK inhibitors are available and provide additional information on safety and tolerability of this class of drug in man. Published data indicate acceptable safety and tolerability of these three SYK inhibitors in healthy volunteers (see IB [[c03536505-04](#)]).

BI 894416 plasma exposures in the current trial are expected to be within plasma exposure values that were observed in previous first-in-man trial 1371-0001 and that were associated with good safety and tolerability.

Rifampicin is a recommended inducer of CYP3A in clinical trials and has been used successfully and safely in previous clinical trials in healthy volunteers. The drug has a potential for hepatotoxicity, which is however accounted for by stringent exclusion criteria, liver enzyme measurement as part of safety laboratory examinations and stopping criteria for the individual subject.

## **2. TRIAL OBJECTIVES AND ENDPOINTS**

### **2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS**

#### **2.1.1 Main objectives**

The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416.

#### **2.1.2 Primary endpoints**

The following pharmacokinetic parameters will be determined for BI 894416:

- $AUC_{0-\infty}$  (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
- $C_{\max}$  (maximum measured concentration of the analyte in plasma)

#### **2.1.3 Secondary endpoint**

The following pharmacokinetic parameter will be determined for BI 894416:

- $AUC_{0-tz}$  (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)



### 3. DESCRIPTION OF DESIGN AND TRIAL POPULATION

#### 3.1 OVERALL TRIAL DESIGN AND PLAN

The study will be performed as an open-label, two-treatment, two-period, one-way crossover trial in healthy male subjects in order to compare the test treatment (T) to the reference treatment (R). The treatments will be one oral single dose of 50 mg BI 894416 as tablet formulation (tablet strength: 25 mg) following 7 days of pre-treatment with 600 mg rifampicin q.d. as tablet formulation (tablet strength: 600 mg) (T) and one oral single dose of 50 mg BI 894416 as tablet formulation (tablet strength: 25 mg) given alone (R). In both treatments, BI 894416 is administered in the fasting state. In the first treatment period (Period 1, Visit 2), all subjects are planned to undergo treatment R, and in the second treatment period (Period 2, Visit 3), all subjects are planned to undergo treatment T. For details, refer to Section [4.1](#).

There will be a washout period of at least 10 days between the administrations of BI 894416.

Based on the good safety and tolerability of BI 894416 in trial 1371-0001, the acceptable safety and tolerability of rifampicin in healthy volunteers and the fact that a decrease of BI 894416 exposure is expected when given together with the CYP and P-glycoprotein inducer rifampicin, it is acceptable to treat all subjects entered in this trial in a single cohort, i.e. with Day 1 of each treatment period on the same calendar day.

An overview of all relevant trial activities is provided in the [Flow Chart](#). For visit schedule and details of trial procedures at selected visits, refer to Sections [6.1](#) and [6.2](#), respectively.

#### 3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUP

For relative bioavailability trials, the crossover design is preferred because of its efficiency: since each subject serves as his own control, the comparison between treatments is based on an intra-subject comparison, thus removing inter-subject variability from the comparison between treatments [\[R94-1529\]](#).

Considering the potentially long-lasting induction effect of rifampicin with regards to CYP enzymes, and in order to avoid carry-over effects of rifampicin-induced induction, a one-way crossover design was selected, with administration of rifampicin in the second treatment period only. This design is not expected to lead to systematic errors in the estimation of the treatment effects since nonspecific time effects are unlikely due to the short trial duration.

Due to short half-life of BI 894416 and the sustained induction effect of rifampicin, rifampicin is not administered on Day 1 of period 2.

The open-label treatment is not expected to bias results, since the primary and secondary study endpoints are derived from measurement of plasma concentrations of the analyte. These endpoints are not expected to be affected by knowledge of treatment.

### **3.3 SELECTION OF TRIAL POPULATION**

It is planned that 16 healthy male subjects will enter the study. They will be recruited from the volunteers' pool of the trial site.

Only male subjects will be included in the study because no data on reproductive toxicology are available at this time and because, until availability of data from the 26-week Tg.rash2 carcinogenicity study, study populations are restricted to male volunteers or patients (see IB [[c03536505-04](#)]).

A log of all subjects enrolled into the trial (i.e. who have signed informed consent) will be maintained in the ISF irrespective of whether they have been treated with investigational drug or not.

#### **3.3.1 Main diagnosis for trial entry**

The study will be performed in healthy subjects.

#### **3.3.2 Inclusion criteria**

Subjects will only be included in the trial if they meet the following criteria:

1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
2. Age of 18 to 50 years (inclusive)
3. BMI of 18.5 to 29.9 kg/m<sup>2</sup> (inclusive)
4. Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation

#### **3.3.3 Exclusion criteria**

Subjects will not be allowed to participate, if any of the following general criteria apply:

1. Any finding in the medical examination (including BP, PR or ECG and including the neurological examination) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
8. History of relevant orthostatic hypotension, fainting spells, or blackouts
9. Chronic or relevant acute infections
10. History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
11. Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause QT/QTc interval prolongation)
12. Intake of an investigational drug in another clinical trial within 60 days of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered
13. Smoker (unless the subject quit smoking for at least 3 months prior to first planned administration of trial medication)
14. Alcohol abuse (consumption of more than 24 g per day)
15. Drug abuse or positive drug screening
16. Blood donation of more than 100 mL within 30 days of planned administration of trial medication or intended blood donation during the trial
17. Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
18. Inability to comply with the dietary regimen of the trial site
19. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
20. A history of additional risk factors for *Torsade de Pointes* (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)
21. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

In addition, the following trial-specific exclusion criteria apply:

22. History of relevant neurological disorder affecting the peripheral or central nervous system (this includes, but is not limited to: stroke, epilepsy, inflammatory or atrophic diseases affecting the nervous system, cluster headache or any cancer of the nervous system). Febrile seizures in childhood or adolescence, recovered carpal tunnel syndrome, recovered uncomplicated meningitis, recovered herpes zoster, tension headache, occasional benign tics (e.g. due to stress) or minor para- or dysesthesia (e.g. as a side effect of prior blood withdrawal) do not constitute a history of relevant neurological disorder.
23. History of immunological disease except allergy not relevant to the trial (such as mild hay fever or dust mite allergy) and except asthma in childhood or adolescence
24. History of cancer (other than successfully treated basal cell carcinoma)
25. Liver enzymes (ALT, AST, gGT, AP) above upper limit of normal at the screening examination

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

26. Within 10 days prior to administration of trial medication, use of any drug that could reasonably inhibit platelet aggregation or coagulation (e.g., acetylsalicylic acid)
27. Male subjects with WOCBP partner who are unwilling to use male contraception (condom or sexual abstinence) from time point of first administration of trial medication until 30 days after the last administration of trial medication

For study restrictions, refer to Section [4.2.2](#).

### 3.3.4 Withdrawal of subjects from treatment or assessments

Subjects may discontinue trial treatment or withdraw consent to trial participation as a whole ('withdrawal of consent') with very different implications; please see Sections [3.3.4.1](#) and [3.3.4.2](#) below.

If a subject is removed from or withdraws from the trial prior to the first administration of trial medication, the data of this subject will not be entered in the case report form (CRF) and will not be reported in the clinical trial report (CTR). If a subject is removed from or withdraws from the trial after the first administration of trial medication, this will be documented and the reason for discontinuation must be recorded in the CRF; in addition, the data will be included in the CRF and will be reported in the CTR. At the time of discontinuation, a complete end of trial examination will be performed, if possible, and the information will be recorded in the CRF.

#### 3.3.4.1 Discontinuation of trial treatment

An individual subject will discontinue trial treatment if:

1. The subject wants to discontinue trial treatment, without the need to justify the decision
2. The subject has repeatedly shown to be non-compliant with important trial procedures and, in the opinion of both, the investigator and sponsor representative, is not willing or able to adhere to the trial requirements in the future.
3. The subject needs to take concomitant medication that interferes with the investigational medicinal product or other trial treatment
4. The subject can no longer receive trial treatment for medical reasons (such as surgery, adverse events [AEs], or diseases)
5. The subject has an elevation of AST and/or ALT  $\geq 2$ -fold ULN and/or needs to be followed up according to the DILI checklist provided in the ISF
6. The subject experiences a drug-related AE of severe intensity or a serious AE

In addition to these criteria, the investigator may discontinue subjects at any time based on his or her clinical judgment.

Even if the trial treatment is discontinued, the subject remains in the trial and, given his agreement, will undergo the procedures for early treatment discontinuation and follow up as outlined in the [Flow Chart](#) and Section [6.2.3](#).

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

### **3.3.4.2 Withdrawal of consent to trial participation**

Subjects may withdraw their consent to trial participation at any time without the need to justify the decision. If a subject wants to withdraw consent, the investigator should be involved in the discussion with the subject and explain the difference between trial treatment discontinuation and withdrawal of consent to trial participation, as well as explain the options for continued follow up after trial treatment discontinuation, please see Section [3.3.4.1](#) above

### **3.3.4.3 Discontinuation of the trial by the sponsor**

Boehringer Ingelheim reserves the right to discontinue the trial at any time for any of the following reasons:

1. Failure to meet expected enrolment goals overall or at a particular trial site
2. New toxicological findings, serious adverse events, or any safety information invalidating the earlier positive benefit-risk-assessment. More specifically, the trial will be terminated if more than 50% of the subjects have drug-related and clinically relevant adverse events of moderate or severe intensity, or if at least 1 drug-related serious adverse event is reported
3. Violation of GCP or the CTP impairing the appropriate conduct of the trial-
4. The sponsor decides to discontinue the further development of the investigational product

### **3.3.5 Replacement of subjects**

In case more than 4 subjects do not complete the trial, the Clinical Trial Leader together with the Trial Pharmacokineticist and the Trial Statistician are to decide, if and how many subjects will be replaced. A replacement subject will be assigned a unique trial subject number, and will be assigned to the same treatment as the subject replaces.

## **4. TREATMENTS**

### **4.1 INVESTIGATIONAL TREATMENTS**

The investigational product BI 894416 as tablet formulation has been manufactured by BI Pharma GmbH & Co. KG. Rifampicin tablets will be obtained from a public pharmacy by the trial site.

#### **4.1.1 Identity of the Investigational Medicinal Products**

The characteristics of the test product are given below:

##### Test product 1:

Substance: BI 894416  
Pharmaceutical formulation: Tablet  
Source: BI Pharma GmbH & Co. KG, Germany  
Unit strength: 25 mg  
Posology: 2-0-0  
Route of administration: oral  
Duration of use: 1 day (in treatment periods 1 and 2)

##### Test product 2:

Name: Eremfat® 600 mg  
Substance: Rifampicin  
Pharmaceutical formulation: Film-coated tablet  
Source: Public pharmacy (obtained by the site)  
Holder of marketing authorization:  
Unit strength: 600 mg  
Posology: 0-0-1  
Route of administration: oral  
Duration of use: 7 days (Days -7 to -1 in treatment period 2)

#### **4.1.2 Selection of doses in the trial**

##### Perpetrator (rifampicin)

Rifampicin given at a dosage of 600 mg once daily reflects standard clinical doses and is considered sufficient to yield significant CYP3A induction.

### Victim (BI 894416)

Based on in vitro data, CYP3A is major responsible enzyme for metabolism of BI 894416. Additionally, BI 894416 was determined to be a substrate of CYP1A1, an extrahepatic enzyme expressed in tissues such as lung and small intestine. Concomitant administration of BI 894416 with the strong CYP3A inducer rifampicin may result in reduction of BI 894416 plasma concentrations. It is not expected that plasma concentrations of BI 894416 could increase when given together with rifampicin in this trial, in particular because of the interval of 14 hours between last administration of rifampicin on Day -1 of period 2 and the following administration of BI 894416 on Day 1 of period 2. This time interval of 14 hours makes any inhibitory effects of rifampicin that could potentially increase plasma concentrations of BI 894416, such as inhibition of intestinal P-glycoprotein, unlikely.

For the current trial, a dose of 50 mg BI 894416 is selected.

see IB [c03536505-04](#)), and it is in the range of doses that were given in first-in-man trial 1371-0001 to healthy volunteers and that were associated with good safety and tolerability.

In the SRD part of trial 1371-0001, single oral doses of 3 to 70 mg BI 894416 were given as oral solution formulation under fasting conditions, and available data indicate that, at all doses tested, BI 894416 administration was safe and well tolerated. In the 70 mg dose group of trial 1371-0001, gMean values for  $C_{max}$  and  $AUC_{0-24}$  of 2130 nM and 11100 nM\*h, respectively, were reached [c03536505-04]. In the 54 mg dose group of trial 1371-0001, gMean values for  $C_{max}$  and  $AUC_{0-24}$  of 1240 nM and 6940 nM\*h, respectively, were reached [c03536505-04]. I.e., the ratios of gMean plasma exposure parameters at 70 mg and at 54 mg were approximately 1.7 ( $C_{max}$ ) and 1.6 ( $AUC_{0-24}$ ). These ratios are assessed to be sufficient as safety margins for the current trial, in particular as a decrease of BI 894416 plasma concentrations is expected when given with rifampicin.

#### **4.1.3      Method of assigning subjects to treatment groups**

There is only one treatment sequence investigated in this trial, and each subject will be allocated to the same treatment sequence (R-T). The subjects will be allocated to a study subject number by the method 'first come - first served' prior to first administration of trial medication in the morning of Day 1 of Visit 2. Reference and test treatments will be administered in the sequence specified in the [Flow Chart](#).

Once a subject number has been assigned, it cannot be reassigned to any other subject.

The application of single BI 894416 doses of up to 70 mg (1371-0001) was well tolerated. For details on these results, refer to Sections [1.4.3](#) and [4.1.2](#) of the protocol.

Two possible interactions are known for rifampicin: (1) it causes induction of CYP3A4 and would therefore lead to a decreased BI 894416 exposure, and (2) it can interact with drug transporters which might lead to an increase BI 894416 exposure. By applying rifampicin in the evening and dosing BI 894416 at the next morning (refer to flow chart), an increase of BI 894416 exposure is not expected. Therefore, this dose regime is used in this study and an

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

unexpected increase of BI 894416 exposure, beyond the exposure tested in the preceding study 1371-0001, is unlikely.

Thus, there should be no undue risk for a subject participating in this study. In addition, it is considered an acceptable option that an entire cohort of up to 16 subjects may be dosed on one day, due to (1) the seen good tolerability of up to 70 mg in the SRD study and (2) the application of 50 mg (below the highest tested dose in study 1371-0001) with an expected lower exposure after CYP 3A4 induction.

#### 4.1.4 Drug assignment and administration of doses for each subject

This trial is a one-way crossover study. All subjects will receive the 2 treatments in fixed order. The treatments to be evaluated are outlined in Table [4.1.4: 1](#) below.

Table 4.1.4: 1 Dosage and treatment schedule

Treatment period	Treatment	Substance	Formulation	Unit strength	Dosage	Total dose
1	R (Reference)	BI 894416	Tablet	25 mg	2 tablets as single dose on Day 1	50 mg
2	T (Test)	Rifampicin	Film-coated tablet	600 mg	1 tablet q.d on Days -7 to -1	4200 mg
		BI 894416	Tablet	25 mg	2 tablets as single dose on Day 1	50 mg

Administration of BI 894416 will be performed after subjects have fasted overnight; fasting is to start no later than 10 h before the scheduled dosing.

For administrations of rifampicin, subjects are advised to fast for at least 2 hours before and at least 30 minutes after drug administrations.

The investigator (or authorised designee) will administer the trial medication as an oral dose together with about 240 mL of water to subjects who are in a standing position. For drug administration, the so-called four-eye principle (two-person rule) should be applied. For this, one authorised employee of the trial site should witness the administration of trial medication, and – if applicable – its preparation (e.g. reconstitution), if correct dosage cannot be ensured otherwise.

For restrictions with regard to diet, see Section [4.2.2.2](#).

Subjects will be kept under close medical surveillance until 24 h after BI 894416 administration. During the first 4 h after BI 894416 administration, subjects are not allowed to lie down (i.e. no declination of the upper body of more than 45 degrees from upright posture).

The first rifampicin administration will be followed by a 2-hour post-administration in-house observation period.

The administrations of BI 894416 will be separated by a wash-out phase of at least 10 days.

#### **4.1.5 Blinding and procedures for unblinding**

This Phase I trial will be handled in an open fashion throughout (that is, during the conduct, including data cleaning and preparation of the analysis). This is considered acceptable because the potential for bias seems to be low and does not outweigh practical considerations.

Emergency envelopes will not be provided, because the dose of trial medication is known to investigators and subjects.

#### **4.1.6 Packaging, labelling, and re-supply**

##### BI 894416 tablets

BI 894416 tablets will be provided by BI. They will be packaged and labelled in accordance with local law and the principles of Good Manufacturing Practice.

For details of packing and the description of the label, refer to the ISF.

The telephone number of the sponsor and the name, address and telephone number of the trial site are provided in the subject information form. The EudraCT number is indicated on the title page of this protocol as well as on the subject information and informed consent forms.

No re-supply is planned.

##### Rifampicin tablets

Rifampicin tablets will be obtained by the clinical trial site from a public pharmacy. The drug will be dispensed out of the original, unmodified packages.

#### **4.1.7 Storage conditions**

Drug supplies will be kept in their original packaging and in a secure limited access storage area in accordance with the recommended (labelled) storage conditions. If necessary, a temperature log must be maintained to make certain that the drug supplies are stored at the correct temperature. If the storage conditions are found to be outside the specified range, the clinical trial manager (as provided in the list of contacts) is to be contacted immediately.

#### **4.1.8 Drug accountability**

The investigator or designee will receive the investigational drugs delivered from the sponsor following requirements are fulfilled:

- Approval of the clinical trial protocol by the IRB / ethics committee
- Approval/notification of the regulatory authority, e.g. competent authority
- Availability of the *curriculum vitae* of the Principal Investigator
- Availability of a signed and dated clinical trial protocol

Only authorised personnel documented in the form 'Trial Staff List' may dispense medication to trial subjects. The trial medication must be administered in the manner specified in the CTP.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

The investigator or designee must maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the disposal of unused products. These records will include dates, quantities, batch / serial numbers, expiry ('use-by') dates, and the unique code numbers assigned to the investigational medicinal product and trial subjects. The investigator or designee will maintain records that document adequately that the subjects were provided the doses specified by the CTP and reconcile all investigational medicinal products received from the sponsor. At the time of disposal of remaining trial medication, the investigator or designee must verify that no remaining supplies are in the investigator's possession.

All unused medication will be disposed of locally by the trial site upon written authorisation of the clinical trial leader. Receipt, usage and disposal of trial medication must be documented on the appropriate forms. Account must be given for any discrepancies.

## **4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, RESTRICTIONS**

### **4.2.1 Other treatments and emergency procedures**

There are no special emergency procedures to be followed. No additional treatment is planned. However, if adverse events require treatment, the investigator can authorise symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, kept under supervision at the trial site or transferred to a hospital until all results of medical evaluations are acceptable.

### **4.2.2 Restrictions**

#### **4.2.2.1 Restrictions regarding concomitant treatment**

In principle, no concomitant therapy is allowed. All concomitant or rescue therapies will be recorded (including time of intake on study days) on the appropriate pages of the CRF.

Acetylsalicylic acid or other drugs that may inhibit platelet aggregation or coagulation should be avoided during the entire study.

Paracetamol, diclofenac or other drugs with relevant hepatotoxicity should be avoided during the entire study.

Known inhibitors/inducers of CYP3A and P-glycoprotein should be avoided during the entire study.

If needed, ibuprofen may be given to treat adverse events, e.g. headache.

#### **4.2.2.2 Restrictions on diet and life style**

Poppy-seeds containing foods should not be consumed starting 3 days before the first drug administration in treatment period 1 until after the last PK sample in period 2 in order to avoid false-positive results in the drug screen.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

While admitted to the trial site, the subjects will be instructed not to consume any foods or drinks other than those provided by the staff. Standardised meals will be served at the times indicated in the [Flow Chart](#).

No food is allowed for at least 10 h before and 4 h after intake of BI 894416.

Subjects will be advised to not consume any food within at least 2 h before and 30 min after intake of rifampicin.

On Day 1 of each treatment period, from 1 h before drug intake until lunch, fluid intake is restricted to the water administered with the drug, and an additional 240 mL of water at 2 h and 4 h post-dose (mandatory for all subjects). From lunch until 24 h post-dose, total fluid intake is restricted to 3000 mL.

Grapefruits, Seville oranges (sour or bitter oranges) and their juices, and dietary supplements and products containing St. John's wort (*Hypericum perforatum*) are not permitted from 7 days before the first administration of trial medication until after the last PK sample in the second treatment period is collected.

Alcoholic beverages are not permitted from 2 days before the first administration of trial medication in period 1 until after the last PK sample in period 2 is collected.

Smoking is not allowed during the trial.

Barbecued meat and broccoli should be avoided during the trial.

Methylxanthine-containing drinks or foods (such as coffee, tea, cola, energy drinks, or chocolate) are not allowed from 10 h before until 24 h after each administration of BI 894416.

Excessive physical activity (such as competitive sport) should be avoided from 7 days before the first administration of trial medication until the end of trial examination.

Direct exposure to the sun or exposure to solarium radiation should be avoided during the entire study.

#### **4.3 TREATMENT COMPLIANCE**

Compliance will be assured by administration of all trial medication in the study centre under supervision of the investigating physician or a designee. The measured plasma concentrations of trial medication will provide additional confirmation of compliance.

Subjects who are non-compliant (for instance, who do not appear for scheduled visits or violate trial restrictions) may be removed from the trial and the CRF will be completed accordingly (for further procedures, please see Section [3.3.4.1](#)).

## 5. ASSESSMENTS

### 5.1 ASSESSMENT OF EFFICACY

Not applicable.

### 5.2 ASSESSMENT OF SAFETY

#### 5.2.1 Physical examination

At screening, the medical examination will include demographics, height and body weight, smoking and alcohol history (alcohol history not mandatory to be entered into CRF or to be reported), relevant medical history and concomitant therapy, review of inclusion and exclusion criteria, review of vital signs (BP, PR), 12-lead ECG, laboratory tests, a physical examination, and a neurological examination. At the end of trial examination, it will include review of vital signs, 12-lead ECG, laboratory tests, a physical examination, and a neurological examination.

#### 5.2.2 Vital signs

Systolic and diastolic blood pressures (BP) as well as pulse rate (PR) will be measured by a blood pressure monitor (Dinamap, ) at the times indicated in the [Flow Chart](#), after subjects have rested for at least 5 min in a supine position. All recordings should be made using the same type of blood pressure recording instrument on the same arm, if possible.

#### 5.2.3 Safety laboratory parameters

For the assessment of laboratory parameters, blood and urine samples will be collected by the trial site at the times indicated in the Flow Chart. For safety laboratory parameter sets A and B subjects should be fasted for at least 10 h. For safety laboratory parameter set C, fasting is not required. For retests, at the discretion of the investigator or designee, overnight fasting is not required.

The parameters that will be determined are listed in Tables [5.2.3: 1](#) and [5.2.3: 2](#). Reference ranges will be provided in the ISF, Section 10.

Manual differential white blood cell count or urine sediment examinations will only be performed if there is an abnormality in the automatic blood cell count or in the urinalysis, respectively.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Table 5.2.3: 1

Routine laboratory tests

Functional lab group	BI test name [comment/abbreviation]	A <sup>1</sup>	B <sup>1</sup>	C <sup>1</sup>
Haematology	Haematocrit Haemoglobin Red Blood Cell Count/Erythrocytes White Blood Cells/Leucocytes Platelet Count/Thrombocytes (quant)	X X X X X	X X X X X	X X X X X
Automatic WBC differential, relative	Neutrophils/Leukocytes; Eosinophils/Leukocytes; Basophils/Leukocytes; Monocytes/Leukocytes; Lymphocytes/Leukocytes	X	X	X
Automatic WBC differential, absolute	Neutrophil, absol.; Eosinophils, absol.; Basophils, absol.; Monocytes, absol.; Lymphocytes, absol.	X	X	X
Manual differential WBC (if automatic differential WBC is abnormal and clinically relevant in the opinion of the investigator)	Neut. Poly (segs); Neut. Poly (segs), absol.; Neutrophils Bands; Neutrophils Bands, absol.; Eosinophils/Leukocytes; Eosinophils, absol.; Basophils/ Leukocytes; Basophils, absol.; Monocytes/ Leukocytes; Monocytes, absol.; Lymphocytes/Leukocytes; Lymphocytes, absol.			
Coagulation	Activated Partial Thromboplastin Time Prothrombin time – INR (International Normalization Ratio)	X X	X X	-- --
Enzymes	AST [Aspartate transaminase] /GOT, SGOT ALT [Alanine transaminase] /GPT, SGPT Alkaline Phosphatase Gamma-Glutamyl Transferase	X X X X	X X X X	X X X X
Hormones	Thyroid Stimulating Hormone	X	--	--
Substrates	Glucose (Plasma) Creatinine Bilirubin, Total Bilirubin, Direct Protein, Total C-Reactive Protein (Quant)	X X X X X X	X X X X X X	-- -- X X -- --
Electrolytes	Sodium Potassium	X X	X X	-- --
Urinalysis1 (Stix)	Urine Nitrite (qual) Urine Protein (qual) Urine Glucose (qual) Urine Ketone (qual) Urobilinogen (qual) Urine Bilirubin (qual) Urine Haemoglobin (qual) Urine WBC/Leucocytes (qual) Urine pH	X X X X X X X X X	X X X X X X X X X	-- -- -- -- -- -- -- -- --
Urine sediment (microscopic examination if haemoglobin, leukocytes nitrite or protein are abnormal in urine)	Only positive findings will be reported (for instance, the presence of sediment bacteria, casts in sediment, squamous epithelial cells, erythrocytes, leukocytes)			

<sup>1</sup> A, B, and C are different sets of laboratory values. The [Flow Chart](#) details at which time point which set is to be investigated.

The tests listed in Table [5.2.3: 2](#) are exclusionary laboratory tests that may be repeated as required. The results will not be entered in the CRF/database and will not be reported in the CTR. Except for drug screening, it is planned to perform these tests during screening only. Drug screening will be performed at screening and prior to each treatment period.

**Table 5.2.3: 2** Exclusionary laboratory tests

Functional lab group	Test name
Drug screening (urine)	Amphetamine/MDA Barbiturates Benzodiazepine Cannabis Cocaine Methadone Methamphetamines/MDMA/XTC Opiates Phencyclidine Tricyclic antidepressants
Cotinine test (urine)	Cotinine
Infectious serology (blood)	Hepatitis B surface antigen (qualitative) Hepatitis B core antibody (qualitative) Hepatitis C antibodies (qualitative) HIV-1 and HIV-2 antibody (qualitative)

To encourage compliance with alcoholic restrictions, a breath alcohol test (e.g. Alcotest® 7410, ) will be performed prior to each treatment period, and may be repeated at any time during the study at the discretion of an investigator or designee. The results will not be included in the CTR.

The laboratory tests listed in Tables [5.2.3: 1](#) and [5.2.3: 2](#) will be performed at with the exception of drug screening tests and the Cotinine test at screening. These tests will be performed at the trial site using Multidrogen Pipettier ( ), or comparable test systems.

Laboratory data will be transmitted electronically from the laboratory to the trial site.

#### **5.2.4      Electrocardiogram**

Twelve-lead ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a computerised electrocardiograph ( ) at the times provided in the [Flow Chart](#).

To achieve a stable heart rate at rest and to assure high quality recordings, the site personnel will be instructed to assure a relaxed and quiet environment, so that all subjects are at complete rest.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

All ECGs will be recorded for a 10 sec duration after subjects have rested for at least 5 min in a supine position. ECG assessment will always precede all other study procedures scheduled for the same time to avoid compromising ECG quality.

All ECGs will be stored electronically on the Muse CV Cardiology System ( ). Electrode placement will be performed according to the method of Wilson, Goldberger and Einthoven modified by Mason and Likar (hips and shoulders instead of ankles and wrists).

All locally printed ECGs will be evaluated by the investigator or a designee. Abnormal findings will be reported as AEs (during the trial) or baseline conditions (at screening) if assessed to be clinically relevant by the investigator. Any ECG abnormalities will be carefully monitored and, if necessary, the subject will be removed from the trial and will receive the appropriate medical treatment.

ECGs may be repeated for quality reasons (for instance, due to alternating current artefacts, muscle movements, or electrode dislocation) and the repeated ECG will be used for analysis. Additional (unscheduled) ECGs may be collected by the investigator for safety reasons.

## **5.2.5      Other safety parameters**

### **5.2.5.1      Neurological examination**

At Screening and at EoTrial examination, a physical neurological examination will be performed. Upon investigator judgment, additional neurological examinations may be added at any time during the trial, for individual subjects or for the whole treatment group.

The neurological examination will include the following assessments:

- Eye movement
- Pupil size and pupil reactivity
- Reflexes
- Assessment of muscle strength
- Gait
- Romberg test
- Tremor
- Point-to-point movements
- Sensitivity

### Documentation, Assessment, and Reporting

Results will be documented in source data at the clinical trial site and assessed for clinical relevance by an investigator, deputy investigator or sub-investigator. Clinically relevant findings of the neurological examination will be reported as Adverse Events (during the trial) or as baseline conditions (at screening). Case narratives may be written if necessary.

## **5.2.6 Assessment of adverse events**

### **5.2.6.1 Definitions of adverse events**

#### **5.2.6.1.1 Adverse event**

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

The following should also be recorded as an AE in the CRF and BI SAE form (if applicable):

- Worsening of the underlying disease or of other pre-existing conditions
- Changes in vital signs, ECG, physical examination, and laboratory test results, if they are judged clinically relevant by the investigator

If such abnormalities already pre-exist prior to trial inclusion, they will be considered as baseline conditions and should be collected in the eCRF only.

#### **5.2.6.1.2 Serious adverse event**

A serious adverse event (SAE) is defined as any AE which fulfils at least one of the following criteria:

- Results in death
- Is life-threatening, which refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if more severe
- Requires inpatient hospitalisation
- Requires prolongation of existing hospitalisation
- Results in persistent or significant disability or incapacity
- Is a congenital anomaly/birth defect
- Is deemed serious for any other reason if it is an important medical event when based upon appropriate medical judgment which may jeopardise the patient and may require medical or surgical intervention to prevent one of the other outcomes listed in the above definitions. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation or development of dependency or abuse

#### **5.2.6.1.3 AEs considered 'Always Serious'**

Cancers of new histology and exacerbations of existing cancer must be classified as a serious event regardless of the time since discontinuation of the trial medication and must be reported

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

as described in [5.2.6.2](#), Subsections ‘AE Collection’ and ‘AE reporting to sponsor and timelines’.

In accordance with the European Medicines Agency initiative on Important Medical Events, Boehringer Ingelheim has set up a list of further AEs, which, by their nature, can always be considered to be ‘serious’ even though they may not have met the criteria of an SAE as defined above.

The latest list of ‘Always Serious AEs’ can be found in the eDC system, an electronic data capture system which allows the entry of trial data at the trial site. These events should always be reported as SAEs as described above.

#### 5.2.6.1.4 Adverse events of special interest

The term adverse events of special interest (AESI) relates to any specific AE that has been identified at the project level as being of particular concern for prospective safety monitoring and safety assessment within this trial, e.g. the potential for AEs based on knowledge from other compounds in the same class. AESIs need to be reported to the sponsor’s Pharmacovigilance Department within the same timeframe that applies to SAEs, please see Section [5.2.6.2.2](#).

The following are considered as AESIs:

- **Hepatic injury**  
A hepatic injury is defined by the following alterations of hepatic laboratory parameters:
  - o An elevation of AST (aspartate transaminase) and/or ALT (alanine transaminase)  $\geq 3$ -fold ULN combined with an elevation of total bilirubin  $\geq 2$ -fold ULN measured in the same blood sample, or
  - o Aminotransferase (ALT, and/or AST) elevations  $\geq 10$  fold ULN

These lab findings constitute a hepatic injury alert and the subjects showing these lab abnormalities need to be followed up according to the ‘DILI checklist’ provided in the ISF or in eDC, as applicable. In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should make sure that these parameters are analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the procedures described in the DILI checklist should be followed.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

#### 5.2.6.1.5 Intensity (severity) of AEs

The intensity (severity) of the AE should be judged based on the following:

Mild: Awareness of sign(s) or symptom(s) that is/are easily tolerated

Moderate: Sufficient discomfort to cause interference with usual activity

Severe: Incapacitating or causing inability to work or to perform usual activities

#### 5.2.6.1.6 Causal relationship of AEs

Medical judgment should be used to determine the relationship, considering all relevant factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, confounding factors such as concomitant medication, concomitant diseases and relevant history.

Arguments that may suggest that there is a reasonable possibility of a causal relationship could be:

- The event is consistent with the known pharmacology of the drug
- The event is known to be caused by or attributed to the drug class
- A plausible time to onset of the event relative to the time of drug exposure
- Evidence that the event is reproducible when the drug is re-introduced
- No medically sound alternative aetiologies that could explain the event (e.g. pre-existing or concomitant diseases, or co-medications)
- The event is typically drug-related and infrequent in the general population not exposed to drugs (e.g. Stevens-Johnson syndrome)
- An indication of dose-response (i.e. greater effect size if the dose is increased, smaller effect size if dose is reduced)

Arguments that may suggest that there is no reasonable possibility of a causal relationship could be:

- No plausible time to onset of the event relative to the time of drug exposure is evident (e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks of drug administration; an allergic reaction weeks after discontinuation of the drug concerned)
- Continuation of the event despite the withdrawal of the medication, taking into account the pharmacological properties of the compound (e.g. after 5 half-lives). Of note, this criterion may not be applicable to events whose time course is prolonged despite removing the original trigger
- Additional arguments amongst those stated before, like alternative explanation (e.g. situations where other drugs or underlying diseases appear to provide a more likely explanation for the observed event than the drug concerned)
- Disappearance of the event even though the trial drug treatment continues or remains unchanged

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

### 5.2.6.2 Adverse event collection and reporting

#### 5.2.6.2.1 AE collection

Upon enrolment into a trial, the subject's baseline condition is assessed (for instance, by documentation of medical history/concomitant diagnoses), and relevant changes from baseline are noted subsequently.

Subjects will be required to report spontaneously any AEs as well as the time of onset, end time, and intensity of these events. In addition, each subject will be regularly assessed by the medical staff throughout the clinical trial and whenever the investigator deems necessary. As a minimum, subjects will be questioned for AEs (and concomitant therapies) at the time points indicated in the [Flow Chart](#). Assessment will be made using non-specific questions such as 'How do you feel?'. Specific questions will be asked wherever necessary in order to more precisely describe an AE.

A carefully written record of all AEs shall be kept by the investigator in charge of the trial. Records of AEs shall include data on the time of onset, end time, intensity of the event, and any treatment or action required for the event and its outcome.

The following must be collected and documented on the appropriate CRF(s) by the investigator:

- From signing the informed consent onwards until an individual subject's end of trial:
  - All AEs (serious and non-serious) and all AESIs
  - The only exception to this rule are AEs (serious and non-serious) and AESIs in Phase I trials in healthy volunteers, when subjects discontinue from the trial due to screening failures prior to administration of any trial medication. In these cases, the subjects' data must be collected at trial site but will not be entered in the CRF or trial database and will not be reported in the CTR.
- After the individual subject's end of trial:
  - The investigator does not need to actively monitor the subject for AEs but should only report any occurrence of cancer and related SAEs and related AESIs of which the investigator may become aware of by any means of communication, e.g. phone call. Those AEs should, however, not be reported in the CRF.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

#### **5.2.6.2.2 AE reporting to the sponsor and timelines**

The Investigator must report SAEs, AESIs, and non-serious AEs which are relevant for the reported SAE or AESI, on the BI SAE form via fax immediately (within 24 hours) to the sponsor's unique entry point (country specific contact details will be provided in the ISF). The same timeline applies if follow-up information becomes available. In specific occasions the Investigator could inform the sponsor upfront via telephone. This does not replace the requirement to complete and fax the BI SAE form.

With receipt of any further information to these events, a follow-up SAE form has to be provided. For follow-up information, the same rules and timeline apply as for initial information.

#### **5.2.6.2.3 Information required**

All (S)AEs, including those persisting after the individual subject's end of trial, must be followed up until they have resolved, have been sufficiently assessed as 'chronic' or 'stable', or no further information can be obtained.

### **5.3 DRUG CONCENTRATION MEASUREMENTS AND PHARMACOKINETICS**

#### **5.3.1 Assessment of pharmacokinetics**

For the assessment of pharmacokinetics, blood and urine samples will be collected at the time points / time intervals indicated in the [Flow Chart](#). The actual sampling times will be recorded and used for determination of pharmacokinetic parameters.

#### **5.3.2 Methods of sample collection**

##### **5.3.2.1 Blood sampling for pharmacokinetic analysis**

###### **BI 894416**

For quantification of BI 894416 concentrations in plasma, 2.7 mL of blood will be drawn from an antecubital or forearm vein into a K<sub>2</sub>-EDTA (dipotassium ethylenediaminetetraacetic acid)-anticoagulant blood drawing tube at the times indicated in the Flow Chart. Blood will be withdrawn by means of either an indwelling venous catheter or by venipuncture with a metal needle.

The EDTA-anticoagulated blood samples will be centrifuged for approximately 10 min at approximately 2000 g to 4000 g and at 4 to 8 °C. Two plasma aliquots will be obtained and stored in polypropylene tubes. The first aliquot should contain at least 0.5 mL of plasma. The process from blood collection until transfer of plasma aliquots into the freezer should be completed within 90 min, with interim storage of blood samples and aliquots at room temperature. The time each aliquot was placed in the freezer will be documented. Until transfer on dry ice to the analytical laboratory, the aliquots will be stored upright at approximately -20°C or below at the trial site. The second aliquot will be transferred to the analytical laboratory after the bioanalyst has acknowledged safe arrival of the first aliquot. At

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

the analytical laboratory, the plasma samples will be stored at approximately -20 °C or below until analysis.

At a minimum, the sample tube labels should list BI trial number, subject number, visit, planned sampling time, and the analyte “BI 894416”. Further information such as matrix may also be provided.

#### Rifampicin

For quantification of rifampicin concentrations in plasma, 2.7 mL of blood will be drawn from an antecubital or forearm vein into a K<sub>2</sub>-EDTA (dipotassium ethylenediaminetetraacetic acid)-anticoagulant blood drawing tube at the times indicated in the [Flow Chart](#). Blood will be withdrawn by means of either an indwelling venous catheter or by venepuncture with a metal needle.

The EDTA-anticoagulated blood samples will be centrifuged for approximately 10 min at approximately 2000 g to 4000 g and at 4 to 8 °C. Two plasma aliquots will be obtained and stored in polypropylene tubes. The first aliquot should contain at least 0.5 mL of plasma. The process from blood collection until transfer of plasma aliquots into the freezer should be completed within 60 min, with interim storage of blood samples and aliquots on ice. The time each aliquot was placed in the freezer will be documented. Until transfer on dry ice to the analytical laboratory, the aliquots will be stored upright at approximately -70°C or below at the trial site. The second aliquot will be transferred to the analytical laboratory after the bioanalyst has acknowledged safe arrival of the first aliquot. At the analytical laboratory, the plasma samples will be stored at approximately -70°C or below until analysis.

At a minimum, the sample tube labels should list BI trial number, subject number, visit, planned sampling time, and the analyte “rifampicin”. Further information such as matrix may also be provided.

#### Further use

After completion of the quantification of BI 894416 or rifampicin in plasma, the plasma samples may be used for analysis of rifampicin at additional time points, for analysis of metabolites of BI 894416 or rifampicin (including, if applicable, re-analysis of parent compound) or for further methodological investigations (e.g. for stability testing). However, only data related to the analytes and/or their metabolite(s) including anti-drug antibodies (if applicable) will be generated by these additional investigations. The study samples will be discarded after completion of the additional investigations but not later than 5 years after the CTR is archived.

The results of any further investigations are not planned to be part of the CTR but can be included into the CTR if necessary.

### **5.3.3      Analytical determinations**

#### **5.3.3.1    Analytical determination of analyte plasma concentration**

BI 894416 and rifampicin concentrations in plasma will be determined by a validated LC-MS/MS (liquid chromatography tandem mass spectrometry) assay. All details of the analytical method will be available prior to the start of sample analysis.

### 5.3.3.2 Analytical determination of analyte urine concentration

BI 894416 concentrations in urine will be determined by a validated LC-MS/MS assay. All details of the analytical method will be available prior to the start of sample analysis.

## 5.4 BIOBANKING

Not applicable.

## 5.6 APPROPRIATENESS OF MEASUREMENTS

All measurements performed during this trial are standard measurements and will be performed in order to monitor subjects' safety and to determine pharmacokinetic parameters in an appropriate way. The scheduled measurements will allow monitoring of changes in vital signs, standard laboratory values, and ECG parameters that might occur as a result of administration of trial medication. The safety assessments are standard, are accepted for evaluation of safety and tolerability of orally administered drugs, and are widely used in clinical trials. The pharmacokinetic parameters and measurements outlined in Section [5.3.2.1.2](#), [2.1.3](#), and [2.2.2.1](#) are generally used assessments of drug exposure.

Due to reversible neurologic effects observed in dog studies at high exposures, a neurological examination is performed at Screening to ensure that no subject with a clinically relevant finding in the neurological examination is included into the trial. Upon investigator judgment, additional neurological examinations may be added at any time during the trial, for individual subjects or for the whole treatment group.

## 6. INVESTIGATIONAL PLAN

### 6.1 VISIT SCHEDULE

Exact times of measurements outside the permitted time windows will be documented. The acceptable time windows for screening and the end of trial examination are provided in the [Flow Chart](#).

Study measurements and assessments scheduled to occur 'before' trial medication administration on Day 1 are to be performed and completed within a 3 h-period prior to the trial drug administration.

The acceptable deviation from the scheduled time for vital signs, ECG, and laboratory tests will be  $\pm$  60 min.

If scheduled in the [Flow Chart](#) at the same time as a meal, blood sampling, vital signs, and 12-lead ECG recordings have to be done first. Furthermore, if several measurements including venepuncture are scheduled for the same time, venepuncture should be the last of the measurements due to its inconvenience to the subject and possible influence on physiological parameters.

For planned blood sampling times, refer to the [Flow Chart](#). While these nominal times should be adhered to as closely as possible, the actual sampling times will be recorded and used for the determination of pharmacokinetic parameters.

For time point 34 h (planned time) after BI 894416 administration, a time window of  $\pm$  60 min will be allowed for PK blood sampling. For time point 48 h (planned time) after BI 894416 administration, a time window of  $\pm$  120 min will be allowed for PK blood sampling.

If a subject misses an appointment, it will be rescheduled if possible. The relevance of measurements outside the permitted time windows will be assessed no later than at the Report Planning Meeting.

### 6.2 DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS

#### 6.2.1 Screening period

After having been informed about the trial, all subjects will provide written informed consent in accordance with GCP and local legislation prior to enrolment in the study.

For information regarding laboratory tests (including drug and virus screening), ECG, vital signs, physical examination, and neurological examination, refer to Sections [5.2.1](#) to [5.2.5](#).

#### 6.2.2 Treatment periods

Samples for genotyping will be taken from all volunteers prior to first drug administration in period 1 (for details, see Section [5.5.1](#)).

Each subject is expected to participate in 2 treatment periods (Period 1: Days 1 to 3; Period 2: Days -7 to 3). At least 10 days will separate administrations of BI 894416 in the first and second treatment periods.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

On Day 1 of treatment period 1 / Day -1 of treatment period 2, study participants will be admitted to the trial site and kept under close medical surveillance for at least 24 h following BI 894416 administration. The subjects will then be allowed to leave the trial site after formal assessment and confirmation of their fitness.

In addition, on Day -7 of treatment period 2, subjects will be admitted to the trial site and kept under close medical surveillance for at least 2 h following the first rifampicin administration. The subjects will then be allowed to leave the trial site after formal assessment and confirmation of their fitness.

On all other study days, subjects will be treated in an ambulatory fashion.

For details on time points and procedures for collection of plasma and urine samples for PK analysis, refer to [Flow Chart](#) and Section [5.3.2](#).

The safety measurements performed during the treatment period are specified in Section [5.2](#) of this protocol and in the [Flow Chart](#). For details on times of all other trial procedures, refer to the [Flow Chart](#). AEs and concomitant therapy will be assessed continuously from screening until the end of trial examination.

### 6.2.3 Follow-up period and trial completion

For AE assessment, laboratory tests, recording of ECG and vital signs, physical examination, and neurological examination during the follow-up period, see Sections [5.2.1](#) to [5.2.6](#).

Subjects who discontinue treatment before the end of the planned treatment period should undergo the EoTrial Visit.

All abnormal values (including laboratory parameters) that are assessed as clinically relevant by the investigator will be monitored using the appropriate tests until a return to a medically acceptable level is achieved. (S)AEs persisting after a subject's EoTrial Visit must be followed until they have resolved, have been sufficiently characterised, or no further information can be obtained.

## 7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE

### 7.1 STATISTICAL DESIGN – MODEL

The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416 (50 mg) in plasma when given as oral single dose together with multiple oral doses of rifampicin (600 mg) (Test, T) as compared to when given alone as oral single dose (Reference, R) on the basis of the primary and secondary pharmacokinetic endpoints, as listed in Section [2.1.2](#) and [2.1.3](#). The trial is designed to allow intra-subject comparisons and will be evaluated statistically by use of a linear model for logarithmically transformed PK endpoints.

The assessment of safety and tolerability is a further objective of this trial, and will be evaluated by descriptive statistics for the parameters specified in Section [2.2.2.2](#).

### 7.2 NULL AND ALTERNATIVE HYPOTHESES

The effect of rifampicin on the pharmacokinetics of BI 894416 in plasma after test vs. reference treatment will be estimated by the ratios of the geometric means (test/reference), and their corresponding 2-sided 90% confidence intervals (CIs) will be provided. This method corresponds to the two one-sided t-test procedure, each at the 5% significance level. Since the main focus is on estimation and not testing, a formal hypothesis test and associated acceptance range is not specified.

### 7.3 PLANNED ANALYSES

#### Analysis sets

Statistical analyses will be based on the following analysis sets:

- Treated set (TS): The treated set includes all subjects who were treated with at least one dose of study drug. The treated set will be used for safety analyses.
- Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the treated set (TS) who provide at least one PK endpoint that was defined as primary or secondary and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability (as specified in the following subsection ‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he contributes only one PK parameter value for one period to the statistical assessment. Descriptive and model based analyses of PK parameters will be based on the PKS.

Adherence to the protocol will be assessed by the trial team. Important protocol deviation (IPD) categories will be suggested in the IQRMP, IPDs will be identified no later than in the Report Planning Meeting, and the IPD categories will be updated as needed.

### Pharmacokinetics

The pharmacokinetic parameters listed in Section [2.1](#) for drug BI 894416 will be calculated according to the relevant SOP of the Sponsor ([001-MCS-36-472](#)).

Plasma concentration data and parameters of a subject will be included in the statistical pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the criteria specified below). Exclusion of a subject's data will be documented in the CTR.

Relevant protocol deviations may be

- Incorrect trial medication taken, i.e. the subject received at least one dose of trial medication the subject was not assigned to
- Incorrect dose of trial medication taken
- Use of restricted medications

Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if for example

- The subject experienced emesis that occurred at or before two times median  $t_{max}$  of the respective treatment (Median  $t_{max}$  is to be determined excluding the subjects experiencing emesis),
- A predose concentration of BI 894416 is  $>5\% C_{max}$  value of that subject in the respective treatment period
- Missing samples/concentration data at important phases of PK disposition curve

Plasma concentration data and parameters of a subject which is flagged for exclusion will be reported with its individual values but will not be included in the statistical analyses.

Descriptive and inferential statistics of PK parameters will be based on the PKS.

Only concentration values within the validated concentration range and actual sampling times will be used for the calculation of pharmacokinetic parameters. Concentrations used in the pharmacokinetic calculations will be in the same format provided in the bioanalytical report, (that is, to the same number of decimal places provided in the bioanalytical report).

#### **7.3.1 Primary endpoint analyses**

##### Primary analyses

The primary endpoints (refer to Section [2.1.2](#)) will be calculated according to BI Standard Operating Procedure (SOP) 'Standards and processes for analyses performed within Clinical Pharmacokinetics/ Pharmacodynamics' ([001-MCS-36-472](#)).

The statistical model used for the analysis of the primary endpoints will be a mixed effects model on the logarithmic scale. That is, the PK endpoints will be log-transformed (natural logarithm) prior to fitting the mixed effects model. This model will include effects accounting for the following sources of variation: subject and treatment. The effect 'subjects' will be

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

considered as random, whereas treatment will be considered as fixed. The model is described by the following equation:

$y_{km} = \mu + s_m + \tau_k + e_{km}$ , where

$y_{km}$  = logarithm of response measured on subject m receiving treatment k,

$\mu$  = the overall mean,

$s_m$  = the effect associated with the m<sup>th</sup> subject, m = 1, 2, ..., n

$\tau_k$  = the k<sup>th</sup> treatment effect, k = 1, 2,

$e_{km}$  = the random error associated with the m<sup>th</sup> subject who received treatment k.

where  $s_m \sim N(0, \sigma_B^2)$  i.i.d.,  $e_{km} \sim N(0, \sigma_W^2)$  i.i.d. and  $s_m, e_{km}$  are independent random variables.

Point estimates for the ratios of the geometric means (test/reference) for the primary endpoints (see Section [2.1](#)) and their two-sided 90% confidence intervals (CIs) will be provided.

For each endpoint, the difference between the expected means for log(T)-log(R) will be estimated by the difference in the corresponding adjusted means (Least Squares Means). Additionally their two-sided 90% confidence intervals will be calculated based on the residual error from the mixed effects model and quantiles from the t-distribution. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% CIs for each endpoint.

In addition to the model based approach all parameters will be calculated and analysed descriptively.

### 7.3.2 Secondary endpoint analyses

The secondary endpoints (refer to Section [2.1.3](#)) will be calculated according to the BI SOP ‘Standards and processes for analyses performed within Clinical Pharmacokinetics/ Pharmacodynamics’ ([001-MCS-36-472](#)) and will be assessed statistically using the same methods as described for the primary endpoints.

### 7.3.4 Safety analyses

Safety will be analysed based on the assessments described in Section [2.2.2.2](#). All treated subjects (TS, refer to Section [7.2](#)) will be included in the safety analysis. Safety analyses will be descriptive in nature and based on BI standards. No hypothesis testing is planned.

For all analyses, the treatment actually administered (= treatment at onset) to the subject will be used (any deviations from the randomised treatment will be discussed in the minutes of the Report Planning Meeting).

Treatments will be compared in a descriptive way. Tabulations of frequencies/proportions will be used to evaluate categorical (qualitative) data, and tabulations of descriptive statistics will be used to analyse continuous (quantitative) data.

Measurements (such as ECG, vital signs, or laboratory parameters) or AEs will be assigned to treatments (see Section [4.1](#)) based on the actual treatment at the planned time of the measurement or on the recorded time of AE onset (concept of treatment emergent AEs). Therefore, measurements planned or AEs recorded prior to first intake of trial medication in period 1 will be assigned to the screening period, those between treatment with BI 894416 in period 1 and first treatment with rifampicin in period 2 are attributed to the treatment interval “BI 894416 alone”, those between first treatment with rifampicin in period 2 and treatment with BI 894416 in period 2 are attributed to the treatment interval “rifampicin alone” and those occurring between treatment with BI 894416 in period 2 and the individual subject’s end of trial are attributed to the treatment interval “BI 894416 + rifampicin”. These assignments including the corresponding time intervals will be defined in detail in the TSAP. Note that AEs occurring after the last per protocol contact but entered before final database lock will be reported to Pharmacovigilance only and will not be captured in the trial database.

Additionally, further treatment intervals (analysing treatments) may be defined in the TSAP in order to provide summary statistics for time intervals, such as combined treatments, on-treatment totals, or periods without treatment effects (such as screening and follow-up intervals).

Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). Frequency, severity, and causal relationship of AEs will be tabulated by treatment, system organ class, and preferred term. SAEs, AESIs (see Section [5.2.6.1](#)), and other significant AEs (according to ICH E3) will be listed separately.

Previous and concomitant therapies will be presented per treatment group without consideration of time intervals and treatment periods.

Laboratory data will be compared to their reference ranges. Values outside the reference range as well as values defined as possibly clinically significant will be highlighted in the listings. Additionally, differences from baseline will be evaluated.

Vital signs or other safety-relevant data will be assessed with regard to possible on-treatment changes from baseline.

Relevant ECG findings will be reported as AEs.

## **7.4 INTERIM ANALYSES**

No interim analysis is planned.

## **7.5 HANDLING OF MISSING DATA**

### **7.5.1 Safety**

It is not planned to impute missing values for safety parameters.

### **7.5.2 Pharmacokinetics**

Handling of missing PK data will be performed according to the relevant Corporate Procedure ([001-MCS-36-472](#)).

PK parameters that cannot be reasonably calculated based on the available drug concentration-time data will not be imputed.

## **7.6 RANDOMISATION**

In this trial subjects receive both treatments in the same order, thus no randomization for the treatment assignment is performed (see also Section [4.1.3](#)).

## **7.7 DETERMINATION OF SAMPLE SIZE**

It is planned to enter a total of 16 subjects in the trial, including up to 4 non PK evaluable subjects. The planned sample size is not based on a power calculation but is considered sufficient to achieve the aims of this exploratory trial. With this sample size, the following precision in estimating the ratio of geometric means (test/reference) can be expected with 95% probability. Precision is defined as the ratio of upper CI limit to the relative BA estimate. Note that the precision is independent of the actual ratio of geometric means.

The intra-individual coefficient of variation (gCV) was estimated from inter-individual gCV from preliminary PK data of the SRD part of a previous trial using the 54 mg dose (data on file). The observed inter-individual gCV was roughly 27% for  $AUC_{0-\infty}$  and 29% for  $AUC_{0-tz}$ . Assuming a within-subject correlation 0.8 for  $AUC_{0-\infty}$  and  $AUC_{0-tz}$ , the estimated upper 70% CI of the intra-individual gCV was roughly 17% for  $AUC_{0-\infty}$  and 15% for  $AUC_{0-tz}$ .

Assuming a gCV of 17% for BI 894416 and given a sample size of 12 subjects with evaluable data for primary analysis, the precision of the two-sided 90% confidence interval of the bioavailability ratio will be approximately 1.18 for a greater gCV of 22%, the precision would still be approximately 1.24. Table [7.7:1](#) provides an overview of the achievable precision for estimating the ratio of geometric means (test/reference). For illustrative purposes, the expected 90% confidence intervals with 95% tolerance probability are displayed for different values of the ratios T/R of geometric means.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Table 7.7: 1

Precision that can be expected with 95% probability and illustrative two-sided 90% confidence intervals around the ratios of geometric means (T/R) for different gCVs in a one-way crossover trial ( $N=12$ )

gCV [%]	Precision upper CL / relative BA estimate	Ratio [%]*	Lower CL [%]	Upper CL [%]
12	1.12	100	88.94	112.44
12	1.12	150	133.41	168.66
12	1.12	200	177.87	224.88
12	1.12	400	355.75	449.76
17	1.18	100	84.75	118.00
17	1.18	150	127.12	177.00
17	1.18	200	169.49	236.00
17	1.18	400	338.99	472.00
22	1.24	100	80.80	123.76
22	1.24	150	121.20	185.64
22	1.24	200	161.60	247.52
22	1.24	400	323.21	495.04

\*Ratio of geometric means (test/reference) for a PK endpoint is defined by  $\exp(\mu_T)/\exp(\mu_R)$ .

The expected 90% confidence interval limits in the table were derived by

$$\text{CI limit}_{\text{upper},\text{lower}} = \exp(\ln(\theta) \pm \omega),$$

with  $\theta$  being the ratio (T/R) on original scale and  $\omega$  the distance from the estimate  $\theta$  to either confidence interval limit on the log-scale, which was obtained from the achievable precision on the original scale.

The calculation was performed as described by Julius [R11-5230] using R Version 3.5.1.

## **8. INFORMED CONSENT, TRIAL RECORDS, DATA PROTECTION, PUBLICATION POLICY, AND ADMINISTRATIVE STRUCTURE**

The trial will be carried out in compliance with the protocol, the ethical principles laid down in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU regulation 536/2014, and other relevant regulations. Investigators and site staff must adhere to these principles.

Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the responsibility of the subject's treating physician.

The investigator will inform the sponsor immediately of any urgent safety measures taken to protect the trial subjects against any immediate hazard, as well as of any serious breaches of the protocol or of ICH GCP.

The Boehringer Ingelheim transparency and publication policy can be found on the following web page: [trials.boehringer-ingelheim.com](http://trials.boehringer-ingelheim.com). As a general rule, no trial results should be published prior to archiving of the CTR.

The terms and conditions of the insurance coverage are made available to the investigator and the subjects, and are stored in the ISF.

### **8.1 TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT**

This trial will be initiated only after all required legal documentation has been reviewed and approved by the respective Institutional Review Board (IRB / Independent Ethics Committee (IEC and competent authority (CA) according to national and international regulations. The same applies for the implementation of changes introduced by amendments.

Prior to a subject's participation in the trial, written informed consent must be obtained from each subject (or the subject's legally accepted representative) according to ICH-GCP and to the regulatory and legal requirements of the participating country. Each signature must be personally dated by each signatory and the informed consent and any additional subject-information form retained by the investigator as part of the trial records. A signed copy of the informed consent and any additional subject information must be given to each subject or the subject's legally accepted representative.

The subject must be given sufficient time to consider participation in the trial. The investigator or delegate obtains written consent of the subject's own free will with the informed consent form after confirming that the subject understands the contents. The investigator or delegate must sign (or place a seal on) and date the informed consent form. If a trial collaborator has given a supplementary explanation, the trial collaborator also signs (or places a seal on) and dates the informed consent.

Re-consenting may become necessary when new relevant information becomes available and should be conducted according to the sponsor's instructions.

The consent and re-consenting process should be properly documented in the source documentation.

## **8.2 DATA QUALITY ASSURANCE**

A risk-based approach is used for trial quality management. It is initiated by the assessment of critical data and processes for trial subject protection and reliability of the results as well as identification and assessment of associated risks. An Integrated Quality and Risk Management Plan documents the rationale and strategies for risk management during trial conduct including monitoring approaches, vendor management and other processes focusing on areas of greatest risk.

Continuous risk review and assessment may lead to adjustments in trial conduct, trial design or monitoring approaches.

A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor's designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will have access to all medical records, the investigator's trial-related files and correspondence, and the informed consent documentation of this clinical trial.

## **8.3 RECORDS**

CRFs for individual subjects will be provided by the sponsor. For drug accountability, refer to Section [4.1.8](#).

### **8.3.1 Source documents**

In accordance with regulatory requirements, the investigator should prepare and maintain adequate and accurate source documents and trial records for each trial subject that include all observations and other data pertinent to the investigation. Source data as well as reported data should follow the 'ALCOA principles' and be attributable, legible, contemporaneous, original, and accurate. Changes to the data should be traceable (audit trail).

Data reported on the CRF must be consistent with the source data or the discrepancies must be explained.

Before providing any copy of subjects' source documents to the sponsor, the investigator must ensure that all subject identifiers (e.g., subject's name, initials, address, phone number, and social security number) have properly been removed or redacted to ensure subject confidentiality.

If the subject is not compliant with the protocol, any corrective action (e.g. re-training) must be documented in the subject file.

For the CRF, data must be derived from source documents, for example:

- Subject identification: sex, year of birth (in accordance with local laws and regulations)
- Subject participation in the trial (substance, trial number, subject number, date subject was informed)
- Dates of subject's visits, including dispensing of trial medication
- Medical history (including trial indication and concomitant diseases, if applicable)
- Medication history

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

- AEs and outcome events (onset date [mandatory], and end date [if available])
- SAEs (onset date [mandatory], and end date [if available])
- Concomitant therapy (start date, changes)
- Originals or copies of laboratory results and other imaging or testing results, with proper documented medical evaluation (in validated electronic format, if available)
- ECG results (original or copies of printouts)
- Completion of subject's participation in the trial (end date; in case of premature discontinuation, document the reason for it, if known)
- Prior to allocation of a subject to a treatment into a clinical trial, there must be documented evidence in the source data (e.g. medical records) that the trial participant meets all inclusion criteria and does not meet any exclusion criteria. The absence of records (either medical records, verbal documented feedback of the subject or testing conducted specific for a protocol) to support inclusion/exclusion criteria does not make the subject eligible for the clinical trial.

### 8.3.2 Direct access to source data and documents

The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review and regulatory inspections. Direct access must be provided to the CRF and all source documents/data, including progress notes, copies of laboratory and medical test results, which must be available at all times for review by the Clinical Research Associate, auditor and regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The accuracy of the data will be verified by direct comparison with the source documents described in Section [8.3.1](#). The sponsor will also monitor compliance with the protocol and GCP.

### 8.3.3 Storage period of records

#### Trial site:

The trial site(s) must retain the source and essential documents (including ISF) according to the local requirements valid at the time of the end of the trial.

#### Sponsor:

The sponsor must retain the essential documents according to the sponsor's SOPs.

## 8.4 EXPEDITED REPORTING OF ADVERSE EVENTS

BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with regulatory requirements.

## 8.5 STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY

Individual subject data obtained as a result of this trial is considered confidential and disclosure to third parties is prohibited with the exceptions noted in Section [8.7](#).

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Data protection and data security measures are implemented for the collection, storage and processing of patient data in accordance with the principles 6 and 12 of the WHO GCP handbook.

Personalised treatment data may be given to the subject's personal physician or to other appropriate medical personnel responsible for the subject's welfare. Data generated at the site as a result of the trial need to be available for inspection on request by the participating physicians, the sponsor's representatives, by the IRB / IEC and the regulatory authorities.

#### 8.5.1 Collection, storage and future use of biological samples and corresponding data

Measures are in place to comply with the applicable rules for the collection, storage and future use of biological samples and clinical data, in particular

- Sample and data usage has to be in accordance with the informed consent
- The BI-internal facilities storing biological samples from clinical trial participants as well as the external banking facility are qualified for the storage of biological samples collected in clinical trials.
- An appropriate sample and data management system, incl. audit trail for clinical data and samples to identify and destroy such samples according to ICF is in place
- A fit for the purpose documentation (e.g., biomarker proposal, analysis plan and report) ensures compliant usage
- If applicable, a fit for purpose approach will be used for assay/equipment validation depending on the intended use of the biomarker data

Samples and/or data may be transferred to third parties and other countries as specified in the ICF

#### 8.6 TRIAL MILESTONES

The **start of the trial** is defined as the date of the enrolment of the first subject in the trial.

The **end of the trial** is defined as the 'date of the last visit of the last subject in whole trial' ('Last Subject Completed') or 'end date of the last open AE' or 'date of the last follow-up test' or 'date of an AE has been decided as sufficiently followed-up', whichever is latest.

**Early termination of the trial** is defined as the premature termination of the trial for any reason before the end of the trial as specified in this protocol.

**Temporary halt of the trial** is defined as any unplanned interruption of the trial by the sponsor with the intention to resume it.

**Suspension of the trial** is defined as an interruption of the trial based on a Health Authority request.

The EC/competent authority in each participating EU member state will be notified about the trial milestones according to the laws of each member state.

A final report of the clinical trial data will be written only after all subjects have completed the trial in all countries (EU or non-EU), so that all data can be incorporated and considered in the report.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

The sponsor will submit to the EU database a summary of the final trial results within one year from the end of a clinical trial as a whole, regardless of the country of the last patient (EU or non-EU).

## **8.7 ADMINISTRATIVE STRUCTURE OF THE TRIAL**

The trial is sponsored by Boehringer Ingelheim (BI).

The trial will be conducted at

, under the supervision of the Principal Investigator. Relevant documentation on the participating (Principal) Investigators (e.g. their curricula vitae) will be filed in the ISF.

BI has appointed a Clinical Trial Leader, responsible for coordinating all required trial activities, in order to

- Manage the trial in accordance with applicable regulations and internal SOPs
- Direct the clinical trial team in the preparation, conduct, and reporting of the trial
- ensure appropriate training and information of clinical trial managers (CTM), Clinical Research Associates, and investigators of participating trial sites

The trial medication will be provided by the Clinical Trial Supplies Unit, BI Pharma GmbH & Co. KG, Biberach, Germany (BI 894416) or will be obtained by the clinical trial site from a public pharmacy (rifampicin).

Safety laboratory tests will be performed by the local laboratory of the trial site ).

Analysis of BI 894416 concentrations in plasma and urine will be performed at ,

Analysis of rifampicin concentrations in plasma will be performed at

On-site monitoring will be performed by BI or a contract research organisation appointed by BI.

Data management and statistical evaluation will be done by BI or a contract research organization appointed by BI according to BI SOPs.

Tasks and functions assigned in order to organise, manage, and evaluate the trial are defined according to BI SOPs. A list of responsible persons and relevant local information can be found in the ISF.

## **9. REFERENCES**

### **9.1 PUBLISHED REFERENCES**

P03-08008 Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. *Clin Pharmacokinet* 2003;42(9):819-850.

P08-01263 Expert panel report 3: guidelines for the diagnosis and management of asthma: full report 2007 (NIH publication no. 07-4051, revised August 2007). <http://www.nhlbi.nih.gov> ; Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute; 2007.

P14-07656 Mueller F, Fromm MF. Transporter-mediated drug-drug interactions. *Pharmacogenomics* 2011;12(7):1017-1037.

R11-5230 Julious SA. Sample sizes for clinical trials. Boca Raton: Taylor & Francis Group; 2010.

R14-4230 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nature Med* 2012;18(5):716-725.

R15-4770 Blancato J, Graves A, Rashidi B, Moroni M, Tchobé L, Ozdemirli M, Kallakury B, Makambi KH, Marian C, Mueller SC. SYK allelic loss and the role of Syk-regulated genes in breast cancer survival. *Plos One* 2014;9(2):e87610

R15-5470 Mocsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. *Nat Rev Immunol* 2010;10(6):387-402.

R15-5888 Pelaia G, Varella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Maselli R. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. *Mediators Inflamm* 2015;2015:879783

R16-0945 Fahy JV. Type 2 inflammation in asthma - present in most, absent in many. *Nat Rev Immunol* 2015;15:57-65.

R16-4459 Krisenko MO, Geahlen RL. Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer. *Biochim Biophys Acta Mol Cell Res* 2015;1853(1):254-263.

R16-5240 Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets. *Blood* 2008;112(7):2780-2786.

R16-5298 Alsadeq A, Hobeika E, Medgyesi D, Klaesener K, Reth M. The role of the Syk/Shp-1 kinase-phosphatase equilibrium in B cell development and signaling. *J Immunol* 2014;193:268-276.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

R18-0241      Guidance for industry: clinical drug interaction studies - study design, data analysis, and clinical implications (draft guidance, this guidance document is being distributed for comment purposes only) (October 2017, clinical pharmacology).  
<https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf> (access date: 19 January 2018) ; Silver Spring: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2017.

R19-2541      Eremfat 600 mg (Riemser), verschreibungspflichtig (Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SPC), Stand der Information: 03.2019).

R94-1529      Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker Inc; 1992.

## **9.2 UNPUBLISHED REFERENCES**

001-MCS-36-472 Standards and processes for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics. Current version

c03536505-04      Investigator Brochure: BI 894416  
Asthma. 04 March 2019.

n00240179      BI 894416:  
Exploratory 15 day oral (gavage) toxicity study in male rats. Nonclinical Report. 13B105. 29 June 2015.

n00243171      Assessment of pro-proliferative effects of the SYK inhibitor BI 1002494 on human breast cancer cell lines and in silico genetic evaluation of SYK for tumour suppressor characteristics using data from breast cancer patient databases. Nonclinical Report. 2016-i-r-resp3-report1. 11 July 2016.

n00245394      BI 894416: Dose Escalation in Dogs with Assessment of Electroencephalography and Nerve Conduction Velocity. Nonclinical Report. 15R160. 21 February 2017.

U09-1349-01      Relative bioavailability of single doses of 150 mg dabigatran etexilate (capsule) when administered alone, after seven days of dosing with 600 mg rifampicin (tablet), and seven days and fourteen days after last administration of rifampicin in healthy male and female volunteers (an open label, fixed sequence, Phase I study). Clinical Trial Report. 1160.100. 29 October 2009.

U10-1328-01      An open-label, 2-period, fixed-sequence, phase I trial to evaluate the effect of multiple doses of rifampicin on the multiple-dose pharmacokinetics of linagliptin. Clinical Trial Report. 1218.67. 17 February 2010.

U12-1140-01

Relative bioavailability of a single oral dose of 40 mg afatinib given alone and after multiple doses of rifampicin – an openlabel, two-period, fixed sequence clinical phase I trial in healthy male volunteers. Clinical Trial Report. 1200.152. 07 February 2012.

U13-1478-01

Relative bioavailability of a single oral dose of nintedanib given alone and in combination with multiple oral doses of rifampicin in healthy male volunteers (an open-label, two-period, fixed-sequence Phase I trial). Clincal Trial Report. 1199.162. 08 August 2013.

## **10. APPENDICES**

Not applicable.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

## 11. DESCRIPTION OF GLOBAL AMENDMENT(S)

### 11.1 GLOBAL AMENDMENT (REVISED PROTOCOL)

Revised Protocol, due to first submission to BfArM and ethic committee.

<b>Date of amendment (revision)</b>	21 June 2019
<b>EudraCT number</b>	2019-000507-33
<b>EU number</b>	
<b>BI Trial number</b>	1371-0005
<b>BI Investigational Medicinal Product(s)</b>	BI 894416
<b>Title of protocol</b>	Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in healthy male subjects (an open-label, one-way crossover study)
<b>CTP-version 2.0 is the first submission to IRB / IEC / Competent Authority</b>	<input checked="" type="checkbox"/>
<b>To be implemented only after approval of the IRB / IEC / Competent Authorities</b>	<input type="checkbox"/>
<b>To be implemented immediately in order to eliminate hazard – IRB / IEC / Competent Authority to be notified of change with request for approval</b>	<input type="checkbox"/>
<b>Can be implemented without IRB / IEC / Competent Authority approval as changes involve logistical or administrative aspects only</b>	<input type="checkbox"/>
<b>Section to be changed</b>	All sections which address site specific requirements
<b>Description of change</b>	To be consistent with site specific requirements
<b>Rationale for change</b>	(1) Adaption to the local site requirements ( ); (2) Change of CTL responsibilities

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

## 11.2 GLOBAL AMENDMENT 2

<b>Date of amendment</b>	26 July 2019
<b>EudraCT number</b>	2019-000507-33
<b>EU number</b>	
<b>BI Trial number</b>	1371-0005
<b>BI Investigational Medicinal Product(s)</b>	BI 894416
<b>Title of protocol</b>	Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in healthy male subjects (an open-label, one-way crossover study)
<b>To be implemented only after approval of the IRB / IEC / Competent Authorities</b>	<input checked="" type="checkbox"/>
<b>To be implemented immediately in order to eliminate hazard – IRB / IEC / Competent Authority to be notified of change with request for approval</b>	<input type="checkbox"/>
<b>Can be implemented without IRB / IEC / Competent Authority approval as changes involve logistical or administrative aspects only</b>	<input type="checkbox"/>
<b>Section to be changed</b>	4.1.3 Method of assigning subjects to treatment groups  1.2.2 Rifampicin
<b>Description of change</b>	4.1.3 Justification of simultaneous dosing of all subjects on day 1  1.2.2 SmPC Update March 2019 (already submitted)
<b>Rationale for change</b>	4.1.3 Health authority / EC request  1.2.2 Came effected during CTP-Preparation

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

### 11.3 GLOBAL AMENDMENT 3

<b>Date of amendment</b>	09 September 2019
<b>EudraCT number</b>	2019-000507-33
<b>EU number</b>	
<b>BI Trial number</b>	1371-0005
<b>BI Investigational Medicinal Product(s)</b>	BI 894416
<b>Title of protocol</b>	Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in healthy male subjects (an open-label, one-way crossover study)
<b>To be implemented only after approval of the IRB / IEC / Competent Authorities</b>	<input type="checkbox"/>
<b>To be implemented immediately in order to eliminate hazard – IRB / IEC / Competent Authority to be notified of change with request for approval</b>	<input type="checkbox"/>
<b>Can be implemented without IRB / IEC / Competent Authority approval as changes involve logistical or administrative aspects only</b>	<input checked="" type="checkbox"/>
<b>Section to be changed</b>	Title page Flow chart 5.2.3 Safety laboratory parameters 5.3.2.1 Blood sampling for pharmacokinetic analysis
<b>Description of change</b>	Title page: - Department of TMCP was deleted Flow chart: - Footnote 5 was corrected to 10 - Cotinine test was added to screening examination in footnote 1 5.2.3 Safety laboratory parameters: - Erythrocytes was corrected to haemoglobin 5.3.2.1 Blood sampling for pharmacokinetic analysis: - Correction of time and storage conditions for rifampicin samples
<b>Rationale for change</b>	Title page: Due to internal restructure of organisation Flow chart: Correction of inconsistency and typos 5.2.3: Correction of inconsistencies due to quantification method 5.3.2.1: Correction due to new stability data of rifampicin in plasma



## APPROVAL / SIGNATURE PAGE

**Document Number:** c26448055

**Technical Version Number:** 4.0

**Document Name:** clinical-trial-protocol-version-04

**Title:** Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in healthy male subjects (an open-label, one-way crossover study)

### Signatures (obtained electronically)

Meaning of Signature	Signed by	Date Signed
Approval-Therapeutic Area		09 Sep 2019 13:18 CEST
Author-Trial Statistician		09 Sep 2019 13:45 CEST
Author-Trial Clinical Pharmacokineticist		09 Sep 2019 21:21 CEST
Approval-Team Member Medicine		13 Sep 2019 05:36 CEST
Approval-Clinical Trial Leader		13 Sep 2019 08:43 CEST
Verification-Paper Signature Completion		16 Sep 2019 09:11 CEST

(Continued) Signatures (obtained electronically)

<b>Meaning of Signature</b>	<b>Signed by</b>	<b>Date Signed</b>